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INTRODUCTION
This thesis deals with the development and validation of Bioanalytical assay method used 
for the estimation of Alosetron in biological fluids. Before discussing the experimental results a 
brief introduction for method development, biopharmaceutical analysis and preliminary treatment 
of biological samples, extraction procedures for drugs and metabolites from biological samples and 
estimation of drugs in biological sample by LC-MS/MS for Alosetron.
Bio-availability and bio-equivalence studies require very precise and accurate assay 
methods that are well validated to quantify drugs in biological samples. The assay methods have to 
be sensitive enough to determine the biological sample concentration of the drug and/or its 
metabolite(s) for a period of about five elimination half-life after dosage of the drug. The assay 
methods also have to be very selective to ensure reliable data, free from interference of endogenous 
compounds and possible metabolites in the biological samples. In addition, methods have to be as 
robust and cost effective as possible, making of particular importance to bioequivalence studies. 
Above all, the assay methods must be able to withstand the scrutiny of national drug registration 
authorities who judge them on the basis of criteria established by international consensus.
Bioanalytical chemistry is the qualitative and quantitative analysis of drug substances in 
biological fluids (mainly plasma and urine) or tissue. It plays a significant role in the evaluation and 
interpretation of bioavailability, bioequivalence and pharmacokinetic data1. The main phases that 
comprise bioanalytical services are,
 Method development,
 Method validation, 
 Sample analysis (method application).
Owing to increased interdependence among countries in recent times it has become 
necessary for results of many methods to be accepted internationally. Consequently, to assure 
common level of quality, the need for and use of validated methods has increased 2.
Whatever way the analysis is done it must be checked to see whether it does what it was 
intended to do; i.e. it must be validated. Each step in the method must be investigated to determine 
the extent to which environment, matrix, or procedural variables can affect the estimation of analyte 
in the matrix from the time of collection up to the time of analysis 3.
A full validation requires a high workload and should therefore only start when promising 
results are obtained from explorative validation performed during the method development phase. 
The process of validating a method cannot be separated from the actual development of method 
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conditions, because the developer will not know whether the method conditions are acceptable until 
validation studies are performed2. Method development clears the way for the further processes on 
the validation stage. It must be recognized that proper validation requires a lot of work. However, 
this effort is repaid by the time saved when running the method routinely during sample analysis.
1.0 BIOPHARMACEUTICAL ANALYSIS
1.1. NEED FOR BIOPHARMACEUTICAL ANALYSIS
Methods of measuring drugs in biological media are increasingly important related to 
following; 
 Bioavailability and Bioequivalence Studies,
 New Drug Development,
 Clinical Pharmacokinetics,
 Research in Basic Biomedical and Pharmaceutical Sciences.
1.2. ASSAY OF DRUGS AND THEIR METABOLITES
A number of allusions have been made to methods that distinguish drugs from their 
metabolites. Drug metabolism reactions can be divided into phase I and phase II categories. Phase I 
typically involves oxidation, reduction, and hydrolysis reactions. In contrast, phase II 
transformations entail coupling or condensation of drugs.This involves glucoronidation, sulfation, 
aminoacid conjugation, acetylation, and methylation. Except for reduction processes, most phase I 
and phase II reactions yield metabolites that are more polar and hence more water soluble than the 
parent drug. Assays must distinguish between drug and its metabolites. If this fact is ignored, 
erroneous data may be generated. 
1.3. ANALYSIS OF DRUGS IN VARIOUS BIOLOGICAL MEDIA
The most common samples obtained for biopharmaceutical analysis are blood, plasma and 
urine. Faeces are also utilized, especially if the drug or metabolite is poorly absorbed or extensively 
excreted in the bile. Other media that can be utilized includes saliva, and tissue.
The choice of sampling media is determined largely by the nature of the drug study. All most the 
drug levels in a clinical pharmacokinetic study demand the use of blood, urine, and possibly saliva. 
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A bioavailability study may require drug level data in blood and/or urine whereas a drug 
identification or drug abuse problem may be solved with any one type of biological sample.
Detection of a drug or its metabolite in biological media is usually complicated by the 
matrix. Because of this, various types of cleanup procedures involving techniques such as solvent 
extraction and chromatography are employed to effectively separate drug components from 
endogenous biologic material. The ultimate sensitivity and selectivity of the assay method may be 
limited by the efficiency of the cleanup methodology.
If the blood is allowed to clot and is then centrifuged, about 30 to 50% of the original 
volume is collected as serum (upper level). Thus, plasma generally is preferred because of its 
greater yield from blood. Blood, serum or plasma samples can be utilized for drug studies and may 
require protein denaturation steps before further manipulation.
If plasma or serum is used for the procedure, the fresh whole blood should be centrifuged 
immediately at 4000rpm for approximately 5 to 10 min, and the supernatant should be transferred 
by means of a suitable device, such as a Pasteur pipette, to a clean container of appropriate size for 
storage. 
Urine is easiest to obtain from the patient and also permits collection of large and frequently 
more concentrated samples. The lack of protein in a healthy individual's urine obviates the need for 
denaturation steps. Because urine samples are readily obtained and often provide the greatest source 
of metabolites, they are frequently analyzed in drug metabolism studies.
With humans, faeces are collected in an aluminium foil pan placed under a toilet seat. Once 
collected, the foil is folded around the material and the sample lyophilized. Faecalspecimens 
contain high protein content, and difficulties arise in their handling and analysis (even after 
Lyophilization) because of the large ratio of solid mass to drug. Denaturation of protein is usually 
required before further   manipulations are begun.
Saliva and biological media obtained from humans when constant ratio between plasma and 
salivary levels of certain drugs exists via non invasive sampling techniques. Saliva is advantageous 
in drug studies done with children. Although the concentrations of drugs in saliva are rarely equal 
to those in plasma, a constant ratio (over an effective therapeutic range) permits calculation of 
plasma levels based on salivary analysis.
Separation or isolation of drugs and metabolites from biologic samples is performed in order 
to partially purify a sample. In this manner, an analyst can obtain the selectivity and sensitivity 
needed to detect a particular compound and can do so with minimum interference from components 
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of the more complex biological matrix. The number of steps in a separation procedure should be 
kept to a minimum to prevent loss of drug or metabolite. Sometimes, the separation steps are 
preceded by a sample pretreatment.
1.4. STORAGE REQUIREMENTS FOR BIOLOGICAL SAMPLES
In order to avoid decomposition or other potential chemical changes in the drugs to be 
analyzed, biological samples should be frozen immediately upon collection and thawed before 
analysis. When drugs are susceptible to plasma esterases, the addition of esterase inhibitors, such as 
sodium fluoride, to blood samples immediately after collection helps to prevent drug decomposition 
.
When collecting and storing biological samples, the analyst should be wary of artifacts from 
tubing or storage vessels that can contaminate the sample. For example, plastic-ware frequently 
contains the high boiling liquid bis (2-ethylhexyl) phthalate; similarly, the plunger-plugs of 
vacutainers are known to contain tri-butoxyethylphosphate, which can interfere in certain drug 
analysis.
1.5. PRELIMINARY TREATMENT OF BIOLOGICAL SAMPLES
In most cases, preliminary treatment of a sample is needed before the analyst can proceed to 
the measurement step. Analysis is required for drug in samples as diverse as plasma, urine, faeces, 
saliva, bile, sweat, and seminal fluid. Each of these samples has its own set of factors that must be 
considered before an appropriate pretreatment method can be selected. Such factors as texture and 
chemical composition of the sample, degree of drug-protein binding, chemical stability of the drug, 
and types of interferences can affect the final measurement step.
1.5.1. PROTEIN PRECIPITATION OR DENATURATION
Biological materials such as plasma, faeces, and saliva contain significant quantities of 
protein, which can bind a drug. The drug may have to be freed from protein before further 
manipulation. Protein denaturation is important, because the presence of proteins, lipids, salts, and 
other endogenous materials in the sample can cause rapid deterioration of HPLC columns and also 
interfere the assay.
Protein denaturation procedures include the use of tungstic acid, ammonium sulfate, heat, 
alcohol, trichloroacetic acid, and perchloric acid.
Methanol and acetonitrile frequently have been used as protein denaturants of biological 
samples. Methanol sometimes is preferred because it produces a flocculent precipitate and not the 
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gummy mass obtained with acetonitrile. Methanol also gives a clearer supernatant and may prevent 
the drug entrapment that can be observed after acetonitrile precipitation. 
Ultrafiltration and dialysis procedures also have been used to remove proteins from 
biological fluids. These procedures are not widely used because they are slow.
1.5.2. HYDROLYSIS OR CONJUGATES
The presence-of drug metabolites as conjugates, such as glucuronides and sulfates, in 
biological samples cannot be ignored. The effect of a drug depends to a considerable extent on the 
biotransformation that occurs in the human body. Therefore, it may be important to isolate the 
actual conjugates. Samples containing either glucuronideacetals or sulfate esters are usually 
pretreated using enzymatic or acid hydrolysis. The unconjugated metabolites that result from the 
hydrolysis procedure are less hydrophilic than their conjugates and usually can be extracted from 
the biological matrix.
A nonspecific acid hydrolysis can be accomplished by heating a biological sample for 30 min at 90 
to 100°C in 2 to 5N hydrochloric acid. Upon cooling, the pH of the sample can be adjusted to the 
desired level and the metabolite removed by solvent extraction. Particularly stable conjugates 
sometimes require hydrolysis in an autoclave.
1.5.3. HOMOGENIZATION
For samples containing insoluble protein, such as muscle or other related tissues, a 
homogenization or solubilizing step using 1N hydrochloric acid may be required before treating the 
sample further. For gelatinous samples such as seminal fluid or sputum, liquefaction is achieved via
sonication. A solid sample such as faeces can be homogenized with a minimum amount of 
methanol. Homogenization is usually performed with a blade homogenizer (e.g., Warring Blender). 
1.6 EXTRACTION PROCEDURES FOR DRUGS AND METABOLITES FROM 
BIOLOGICAL SAMPLES
After pre treatment of biological material, the next step is usually the extraction of the drugs 
from the biological matrix. All separation procedures use one or more treatments of matrix-
containing solute with some fluid. As extracting solvents are liquid and the biological sample solid 
(e.g., lyophilized faeces), it is an example of liquid-solid extraction. If the extraction involves two 
liquid phases, it is an example of liquid-liquid extraction.
1.6.1 LIQUID-SOLID EXTRACTION
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Liquid - solid extractions occur between a solid phase and a liquid phase, either phase may 
initially contain the drug substance. Among the solids that have been used successfully in the 
extraction (usually via adsorption) of drugs from liquid samples are XAD-2 resin, charcoal, 
alumina, silica gel, and aluminum silicate. Sometimes the drugs are contained in a solid phase, such 
as in lyophilized specimens. Liquid-solid extraction is often particularly suitable for polar 
compounds that would otherwise tend to remain in the aqueous phase. The method could also be 
useful for amphoteric compounds that cannot be extracted easily from water.
Factors governing the adsorption and elution of drugs from the resin column include solvent 
polarity; flow rate of the solvent through the column, and the degree of contact between the solvent 
and with the resin beds. 
In the adsorption process, the hydrophobic portion of the solute that has little affinity for the 
water phase is preferentially adsorbed on the resin surface while the hydrophilic portion of the 
solute remains in the aqueous phase. Alteration in the lipophilic / hydrophilic balance within the 
solute or solvent mix, and not within the resin, affects adsorption of the solute. 
Biological samples can be prepared for cleanup by passing the sample through the resin bed 
where drug (metabolite) components are adsorbed and finally eluted with an appropriate solvent. 
The liquid-solid extraction method provides a convenient isolation procedure for blood samples, 
thus avoiding solvent extraction, protein precipitation, drug losses, and emulsion formulation. It is 
possible; however, that strong drug-protein binding could prevent sufficient adsorption of the drug 
to resin. 
DEHYDRATION METHODS
An aqueous biological sample is treated with a sufficient quantity of anhydrous salt (sodium 
or magnesium sulfate) to create a "dried" mix. This mix is then extracted with a suitable organic 
solvent to remove the desired drug or metabolite.
1.6.2. LIQUID-LIQUID EXTRACTION
Liquid-liquid extraction is probably the most widely used technique because the analyst can 
remove a drug or metabolite from larger concentrations of endogenous materials that might 
interfere with the final analytical determination.  
The technique is simple, rapid, and has a relatively small cost factor per sample. 
The extract containing the drug can be evaporated to dryness, and the residue can be 
reconstituted in a smaller volume of a more appropriate solvent. In this manner, the sample 
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becomes more compatible with a particular analytical methodology in the measurement step, such 
as a mobile phase in LCMS/MS determinations. 
The extracted material can be reconstituted in small volumes (e.g., 100 to 500 µl of solvent), 
thereby extending the sensitivity limits of an assay. It is possible to extract more than one sample 
concurrently. Quantitative recoveries (90% or better) of most drugs can be obtained through 
multiple or continuous extractions.
Partitioning or distribution of a drug between two possible liquid phases can be expressed in 
terms of a partition or distribution coefficient, usually called  partition coefficient is constant only 
for a particular solute, temperature, and pair of solvents used. By knowing the P value for the 
extracted drug and the absolute volumes of the two phases to be utilized, the quantity of drug 
extracted after a single extraction can be obtained. In multiple extractions methodology, the original 
biological sample is extracted several times with fresh volumes of organic solvent until as much 
drug as possible is obtained. Because the combined extracts now contain the total extracted drug, it 
is desirable to calculate the number of extractions necessary to achieve maximum extraction.
FACTORS AFFECTING THE PARTITION COEFFICIENT
Factors that influence partition coefficient and hence recovery of drugs in liquid-liquid 
extraction are choice of solvent, pH, and ionic strength of the aqueous phase. In almost all cases, 
one of the liquid phases is aqueous because of the nature of a biological sample. The second liquid 
is selected by the analyst. It is highly desirable to select an organic solvent that shows greater 
affinity for the drug analyzed, yet leaves contaminants or impurities in the aqueous or biological 
phase. The solvent should be immiscible with an aqueous phase, should have less polarity than 
water, and should solubilize the desired extractable compound to a large extent. It should also have 
a relatively low boiling point so that it can be easily evaporated if necessary. Other considerations 
are cost, toxicity, flammability, and the nature of the solvent. If larger numbers of samples are to be 
extracted, the volume of solvent needed per sample can affect the overall cost of the assay 
procedure. 
It is generally accepted that diethyl ether and chloroform are the solvents of choice for 
acidic and basic drugs, respectively, especially when the identity of the drugs in the samples are 
unknown. In these cases, any chemically neutral drugs are extracted into either solvent depending 
on their relative partition tendencies.
Proper pH adjustment of a biological sample permits quantitative conversion of an ionized 
drug to an un-ionized species, which is more soluble in a nonpolar solvent and therefore, 
extractable from an aqueous environment. In analysis, do determine a known drug or metabolite, 
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the proper pH for extraction can be calculated from the Henderson-Hassel Balch equation using the 
pKa of the compound. If the species to be analyzed is unknown, the pH must be approximated 
based on the chemical nature of the suspected agent.
Third Factor influencing extractability of drugs from biological samples is ionic strength. 
Addition of highly water-soluble ionized salts, such as sodium chloride, to an aqueous phase creates 
a high degree of interaction between the water molecules and the inorganic ions in solution. Fewer 
water molecules are free to interact with an unionized drug. Therefore, the solubility of the drug in 
the aqueous phase decreases, thereby increasing the partitioning or distributing in favor of the non-
polar or organic phase. The technique is commonly called   "salting out."
Either mechanical or manual tumbling, rocking, or vigorous shaking of the samples can 
accomplish mixing of the aqueous organic phases . The percent recovery of a drug vs. time and/or 
type of mixing should be investigated for each biological sample. In many cases, vigorous shaking 
of a sample should be avoided because it leads to emulsification, which can be intractable for 
centrifugation. Emulsification is often observed when organic solvents are used at basic pH 
whereas certain organic solvents such as n-hexane and diethyl ether are less emulsion-prone.
Certain types of amphoteric drugs or drugs that possess extreme water solubility are not 
amenable to classic solvent extraction. In these cases, other types of analytical methodology such as 
ion-pairing must be adopted.
The technique of back-extraction can be applied with success to the analysis of drugs in 
biological samples. The purpose of the methodology is to further purify an extract by removing 
either drug or impurities by additional extractions. 
1.7. CHROMATOGRAPHIC METHODS
The presence of metabolites or more than one drug in a biological sample usually demands a 
more sophisticated separation for their measurement especially, when two or more drugs are of 
similar physical and chemical nature. Chromatography is a separation technique that is based on 
differing affinities of a mixture of solutes between at least two phases. The result is a physical 
separation of the mixture into its various components. The affinities or interactions can be classified 
in terms of a solute adhering to the surface of a polar solid (adsorption), a solute dissolving in a 
liquid (partition), and a solute passing through or impeded by a porous substance based on its 
molecular size (exclusion).
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1.7.1. HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
HPLC is directly derived from classic column chromatography in that a liquid mobile phase 
is pumped under pressure rather than by gravity flow through a column filled with a stationary 
phase. This has resulted in a sharp reduction in separation time, narrower peak zones, and improved 
resolution. The mobile phase is placed in a solvent reservoir for pumping into the system. In the 
case of liquid-solid HPLC, solvents are chosen from the elutropic series. A solvent system is 
usually degassed by vacuum treatment or sonication before use.
1.7.2. LIQUID CHROMATOGRAPHY MASS SPECTROMETRY
Liquid chromatography is a fundamental separation technique in the life sciences and 
related fields of chemistry. Unlike gas chromatography, which is unsuitable for nonvolatile and 
thermally fragile molecules, liquid chromatography can safely separate a very wide range of 
organic compounds, from small-molecule drug metabolites to peptides and proteins.
Traditional detectors for liquid chromatography include refractive index, electrochemical, 
fluorescence, and ultraviolet-visible (UV-Vis) detectors. Some of these generate two dimensional 
data; that is, data representing signal strength as a function of time. Others, including fluorescence 
and diode array UV-Vis detectors, generate three-dimensional data. Three-dimensional data include 
not only signal strength but spectral data for each point in time.
Mass spectrometers also generate three dimensional data. In addition to signal strength, they 
generate mass spectral data that can provide valuable information about the molecular weight, 
structure, identity, quantity, and purity of a sample.
Mass spectral data add specificity that increases confidence in the results of both qualitative 
and quantitative analysis.
For most compounds, a mass spectrometer is more sensitive and far more specific than all 
other LC detectors. It can analyze compounds that lack a suitable chromophore. It can also identify 
components in unresolved chromatographic peaks, reducing the need for perfect chromatography.
Some mass spectrometers have the ability to perform multiple steps of mass spectrometry 
on a single sample. They can generate a mass spectrum, select a specific ion from that spectrum, 
fragment the ion, and generate another mass spectrum; repeating the entire cycle many times. Such 
mass spectrometers can literally deconstruct a complex molecule piece by piece until its structure is 
determined.
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Mass spectral data complements data from other LC detectors. While two compounds may 
have similar UV spectra or similar mass spectra, it is uncommon for them to have both.
1.8. ESTIMATION OF DRUGS IN BIOLOGICAL SAMPLES BY LC-MS/MS
MS has emerged as an ideal technique for the identification of such structurally diverse 
metabolites. When coupled with online HPLC the technique is extremely robust, rapid, sensitive, 
and easily automated. Not surprisingly, LC/MS/MS have become the methods of choice for 
pharmacokinetic studies, yielding concentration versus time data for drug compounds from in vivo 
samples such as plasma.
LC-MS instrument consist of three major components
 LC (to resolve a complex mixture of components)
 An interface (to transport the analyte in to the ion source) of a mass spectrometer
 Mass spectrometer (to ionize and mass analyze the individually resolved components)
Reverse phase (RP) HPLC is a widely pretended mode of chromatography and is a major 
contributing factor to advances made in several areas of pharmaceutical science. Mobile phase 
composition is a very critical in achieving selectivity in RP-HPLC separation. Although a large 
number of buffer system have been used in conventional RP-HPLC, only the volatile ion paring 
reagent can be used in LC-MS analysis.
1.8.1. IONIZATION TECHNIQUES
Interface is used for transporting the analyte into the ion source of a mass spectrometry. The 
different types of ionization techniques are ESI, APCI, APPI most commonly used ionization 
techniques.
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1.8.1.1. ELECTROSPRAY IONIZATION (Turbo spray)
Electrospray relies in part on chemistry to generate analyte ions in solution before the 
analyte reaches the mass spectrometer. The LC eluent is sprayed (nebulized) into a chamber at 
atmospheric pressure in the presence of a strong electrostatic field and heated drying gas. The 
electrostatic field causes further dissociation of the analyte molecules.
             The heated drying gas causes the solvent in the droplets to evaporate. As the droplets 
shrink, the charge concentration in the droplets increases. Eventually, the repulsive force between 
ions with like charges exceeds the cohesive forces and ions are ejected (desorbed) into the gas 
phase. These ions are attracted to and pass through a capillary sampling orifice into the mass 
analyzer.
Some gas-phase reactions, mostly proton transfer and charge exchange, can also occur. 
Between the times, ions are ejected from the droplets and they reach the mass analyzer.
1.8.1.2. ATMOSPHERIC PRESSURE CHEMICAL IONIZATION
In APCI, the LC eluent is sprayed through a heated (typically 250°C – 400°C) vaporizer at 
atmospheric pressure. The heat vaporizes the liquid. The resulting gas-phase solvent molecules are 
ionized by electrons discharged from a corona needle. The solvent ions then transfer charge to the 
analyte molecules through chemical reactions (chemical ionization).
The analyte ions pass through a capillary sampling orifice into the mass analyzer. APCI is 
applicable to a wide range of polar and nonpolar molecules. It rarely results in multiple charging so 
it is typically used for molecules less than 1,500µ. Due to this, and because it involves high 
temperatures, APCI is less well-suited than electrospray for analysis of large biomolecules that may 
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be thermally unstable. APCI is used with normal-phase chromatography more often than 
electrospray is because the analytes are usually nonpolar.
4.1.3. ATMOSPHERIC PRESSURE PHOTO IONIZATION
Atmospheric pressure photo ionization (APPI) for LC-MS/MS is a relatively new technique. 
As in APCI, a vaporizer converts the LC eluent to the gas phase. A discharge lamp generates 
photons in a narrow range of ionization energies. The range of energies is carefully chosen to ionize 
as many analyte molecules as possible while minimizing the ionization of solvent molecules. The 
resulting ions pass through a capillary sampling orifice into the mass analyzer.
APPI is applicable to many of the same compounds that are typically analyzed by APCI. It 
shows particular promise in two applications, highly nonpolar compounds and low flow rates (<100 
µl/min), where APCI sensitivity is sometimes reduced.
In all cases, the nature of the analyte(s) and the separation conditions has a strong influence 
on which ionization technique: electrospray, APCI, or APPI will generate the best results. The most 
effective technique is not always easy to predict.
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1.8.2. MASS ANALYZER (Quadrupole)
A quadrupole mass analyzer consists of four parallel rods arranged in a square. The analyte 
ions are directed down the center of the square. Voltages applied to the rods generate 
electromagnetic fields. These fields determine which mass-to-charge ratio of ions can pass through 
the filter at a given time. Quadrupoles tend to be the simplest and least expensive mass analyzers.
Quadrupole mass analyzers can operate in two modes:
 MRM Mode
 Scanning (scan) mode
 Selected ion monitoring (SIM) mode
In scan mode, the mass analyzer monitors a range of mass-to-charge ratios. In SIM mode, 
the mass analyzer monitors only a few mass to- charge ratios.
SIM mode is significantly more sensitive than scan mode but provides information about 
fewer ions. Scan mode is typically used for qualitative analyses or for quantitation when all analyte 
masses are not known in advance.
SIM mode is used for quantitation and monitoring of target compounds.
1.9. APPLICATIONS OF LC-MS/MS
 Peptide mapping
 Selective detection of compounds in a complex mixture
 Efficient analysis of biological samples
 To identify degradation products in stability studies
 Identification of metabolites
 Quantification of compounds in biological matrix.
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1.10. QUANTITATIVE ANALYSIS 
Three methods are generally used for quantitative analysis. They are the external standard 
method, the internal standard method and the standard addition method.
1.10.1 EXTERNAL STANDARD METHOD
The external standard method involves the use of a single standard or up to three standard 
solutions. The peak area or the height of the sample and the standard used are compared directly or 
the slope of the calibration curve based on standards that contain known concentrations of the 
compounds of interest.
1.10.2. INTERNAL STANDARD METHOD
A widely used technique of quantitation involves the addition of an internal standard to 
compensate for various errors. In this approach, a known compound of a fixed concentration is 
added to the known amount of samples to give separate peaks in the chromatograms, to compensate 
for the losses of the compounds of interest during sample pretreatment steps. Any loss of the 
component of interest will be accompanied by the loss of an equivalent fraction of internal 
standard. The accuracy of this approach obviously dependents on the structural equivalence of the 
compounds of interest and the internal standard.
The requirements for an internal standard must
 Give a completely resolved peak with no interferences,
 Elute close to the compound of interest,
 Behave equivalent to the compounds of interest for analysis like pretreatments, derivative 
formations, etc.,
 Be added at a concentration that will produce a peak area or peak height ratio of about unity 
with the compounds of interest,
 Not be present in the original sample,
 Be stable, unreactive with sample components, column packing and the mobile phase and
 Be commercially available in high purity.
 Free from Drug-drug intraction
The internal standard should be added to the sample prior to sample preparation procedure and 
homogenized with it. Response factor is used to determine the concentration of a sample 
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component in the original sample. The response factor (RF) is the ratio of peak areas of sample
component (Ax) and the internal standard (ISTD) obtained by injecting the same quantity.
1.11. METHOD DEVELOPMENT
The method development and establishment phase defines the chemical assay. 
A bioanalytical method is a set of all procedures involved in the collection, processing, 
storing, and analysis of a biological matrix for an analyte methods employed for quantitative 
determination of drugs and their metabolites in biological fluids are the key determinants in 
generating reproducible and reliable data that in turn are used in the evaluation and interpretation of 
bioavailability, bioequivalency and pharmacokinetics.
Method development involves evaluation and optimization of the various stages of sample 
preparation, chromatographic separation, detection and quantification. To start these works an 
extensive literature survey, reading work done on the same or similar analyte and summarizing 
main starting points for future work is of primary importance. Based on the information from the 
survey, the following can be done.
 Choice of instrument that is suitable for the analysis of analyte of interest.
 Choice of the column associated with instrument of choice, the detector and the mobile 
phase. 
 Choice of internal standard, (It must have similar chromatographic properties of analyte.)
 Choice of extraction procedure, (which is time economical, gives the highest possible 
recovery without interference and has acceptable accuracy and precision.)
Another important issue in method development stage is the choice of internal versus external 
standardization. Internal standardization is common in bioanalytical methods especially with 
chromatographic procedures. For internal standardization, a structural or isotopic analogue of the 
analyte is added to the sample prior to sample pre-treatment and the ratio of the response of the 
analyte to that of the internal standard is plotted against the concentration. Another important point 
is that the tests performed at the stage of method development should be done with the same 
equipment that will actually be used for subsequent routine analysis. The differences found between 
individual instruments representing similar models from the same manufacturer is not surprising 
and should be accounted.
      1.11.1. Optimization of chromatographic conditions
Optimization of liquid chromatography parameters in bio analytical method is mainly objected
towards improvement of resolution, peak shape and removal of interference at analytes Rt.
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In case of LC-MS/MS method because of highly specific and selective detection of
analytes because of MRM detection mode, less effort are needed to for improvement of
resolution.
Generally mobile phase optimization is always preferred prior to stationary phase optimization.
1.11.2. Selection of mobile phase
There are many more restrictions regarding the selection of eluents and eluent components for use
with HPLC-MS methods compared with HPLC- UV methods. Essentially the buffer  
constituents have to be volatile so the usual standby, phosphate, is unacceptable, as are the
other common eluent constituents such as ion- pair reagents, organic amines, etc. Whilst the use
of these eluent components may give acceptable results (at least in the short term), they
would rapidly result in fouling of the source of common atmospheric ionization interfaces. This
would lead to loss in sensitivity and significant down-time as the source was repeatedly cleaned. 
The use of MS detection therefore necessitates a new way of thinking about HPLC eluent.
1.11.3. Organic Modifiers
Firstly a decision must be made regarding the use of methanol or acetonitrile. Methanol is slightly
superior to acetonitrile with ESI since it gives marginally greater response. Methanol is also
preferred since it is reported to give slightly better peak shape for basic compounds in RP- HPLC
than acetonitrile and it is a better solvent for buffer salts.
1.11.4. Mobile Phase Buffering
Wherever acidic or basic samples are separated it is strongly advisable to control mobile
phase pH by adding a buffer. The measurement of pH for a mobile that contains organic solvent
is imprecise, because electrode response tends to drift. Consequently if a pH meter is to be used,
it is strongly recommended that the pH of the buffer should be adjusted before adding organic. In
selecting a particular buffer, several considerations should be kept in mind.
Buffer Capacity - Buffer capacity is determined by pH, buffer pKa and buffer 
concentration. As for the case of a sample compound buffer ionization occurs over a range in pH
given by pKa ± 2. Only in this pH range can the buffer be effective in controlling pH. Therefore,
to be on the safe side, the buffer selected for a particular separation should be used to control 
pH over a range ≈ pKa ± 1.0. For RPC separations, a buffer concentration of 10 to 50 mM
is usually adequate. Higher buffer concentrations also may adversely affect the operation of
HPLC systems constructed of stainless steel. A mobile phase with marginal buffer capacity
will give less reproducible separations for compounds that are practically ionized at the pH of
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the mobile phase. In this case, retention may change from run to run, and distorted peaks may
result. Buffer solubility and stability, possible interaction with the equipment, sample, and/or
column, and the volatility are also of interest for some applications.
1.11.5. Selection of column
When attempting a separation, a reverse-phase, bonded-hydrocarbon column should be selected
first, because such columns have the widest applicability. Fully reacted monomeric bonded C8
packing represent a good compromise for reverse- phase separations, because these materials
have moderate retention, good efficiency and stability, and a useful k' range for a wide variety of
samples. C18 can be used for applications in which maximum retention and sample size is
required. C18 packing sometimes also exhibit superior characteristics for compounds that 
have higher water solubility. Shorter-chain bonded hydrocarbon phases are useful in applications 
involving very strongly retained solutes, or to improve selectivity by the use of the higher
concentrations of water required in the mobile phase for these packing.
As in LLC with mechanically held stationary liquids, retention in normal phase BPC increases
with the polarity of the bonded-stationary phase. Depending on the  organic  functionality,  polar  
BPC  packings  show  significant  selectivity differences when compared to bare silica packings
and to each other and some polar bonded-phase packings are actually more retentive than bare
silica.
Normal-phase BPC columns can be used as an alternative to adsorption chromatography
and one of the most versatile of these materials is the nitrile (CN or cyano-) bonded-phase
materials. Separation of very polar (including water-soluble) samples may require packings such
as diol- or amino-BPC packings. However, if the sample itself is aqueous, a reverse- phase system
should be attempted first, because this approach offers greater sampling convenience.
1.11.6. Selection of internal standard:
An internal standard at a known concentration is normally added to plasma samples and is
utilized to diagnose several potential variations that can occur during sample preparation and 
ongoing analysis.
The structure of the internal standard should be similar to the drug of interest. If this is not 
possible other standards can be used.
Requirements for a proper internal standard:
 Well resolved from the compound of interest and other peaks.
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 Similar retention to the Analyte.
 Should not be in the original sample.
 Should mimic the Analyte in any sample preparation steps.
 Does not have to be chemically similar to Analyte.
 Commercially available in high purity.
 Stable and uncreative with sample or mobile phase.
 Should have a similar detector response to the Analyte for the                      
concentration used.
1.12. METHOD VALIDATION 
The search for the reliable range of a method and continuous application of this knowledge 
is called validation. It can also be defined as the process of documenting that the method under 
consideration is suitable for its intended purpose.
Method validation involves all the procedures required to demonstrate that a particular 
method for quantitative determination of the concentration of an analyte (or a series of analytes) in 
a particular biological matrix is reliable for the intended application. Validation is also a proof of 
the repeatability, specificity and suitability of the method.
Bioanalytical methods must be validated if the results are used to support the registration of 
a new drug or a new formulation of an existing one. Validation is required to demonstrate the 
performance of the method and reliability of results. If a bioanalytical method is claimed to be for 
quantitative biomedical application, then it is important to ensure that a minimum package of 
validation experiments has been conducted and yields satisfactory results.
The guideline for industry by FDA states that the fundamental parameters of validation 
parameters for a bioanalytical method validation are accuracy, precision, selectivity, sensitivity, 
reproducibility and stability. Typical method development and establishment for bioanalytical 
method includes determination of (1) selectivity, (2) accuracy, (3) precision, (4) recovery, (5) 
calibration curve, and (6) stability.
For a bioanalytical method to be considered valid, specific acceptance criteria should be set 
in advance and achieved for accuracy and precision for the validation of the QC samples.
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Validations are subdivided into the following three categories:
1.12.1. FULL VALIDATION
This is the validation performed when developing and implementing a bioanalytical method 
for the first time. Full validation should be performed to support pharmacokinetic, bioavailability, 
and bioequivalence and drug interaction studies in a new drug application (NDA).
1.12.2. PARTIAL VALIDATION
Partial validations are performed when modifications of already validated bioanalytical 
methods are made. Partial validation can range from as little as one intra-assay and precision 
determination to a nearly full validation. Some of the typical bioanalytical method changes that fall 
into this category include bioanalytical method transfer between laboratories or analyst, change in 
methodology, change of matrix within species, change of species within matrix. The decision of 
which parameters to be revalidated depend on the logical consideration of the specific validation 
parameters likely to be affected by the change made to the bioanalytical method.
1.12.3. CROSS VALIDATION
Cross validation is a comparison of validation parameters when two or more bioanalytical 
methods are used to generate data within the same study or across different studies. An example of 
cross validation would be a situation when the original validated bioanalytical method serves as the 
reference and the revised bioanalytical method is the comparator. 
1.12.4. VALIDATION PARAMETERS
The following experimental design is drawn in order to prove the test method is capable to yield 
consistent, reliable and reproducible results within the pre-determined acceptance limits.
Acceptance criteria for the validation parameters are specified in individual experimental design.
Observations and results were recorded in individual method validation data sheets.
The following parameters have been validated.
1. carryover test
2. Selectivity
3. sensitivity
4. matrix effect
5. Linearity
6. Precision and Accuracy
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     7.     Recovery
  8.     Dilution integrity
     9.   Ruggedness
    10.   Stabilities
10.1 Room temperature stability
10.2. Refrigerator stock solution stability
10.3 Bench top stability
10.4 Auto sampler stability
10.5 Long term stability
10.6 Freeze thaw stability
                10.7 Wet Extract Stability      
11. Re-injection stability
12. Concomitant Drug Effect
Acceptance Criteria:
 Precision: The precision calculated for Low and High QC concentrations should be within 15% 
and 20% for the LLOQ QC Concentrations.
 Accuracy: The accuracy calculated for Low and High QC concentrations should be within  15 
% and  20 % for the LLOQ QC Concentration of the nominal value.
 At least 67% of the QC samples should be within 15% of their respective nominal values except 
at LLOQ QC where it should be within 20% of the nominal values. 33% of the QC samples (not all 
replicates at the same concentration) can be out side the above acceptance limits. At least 50% of 
QC samples at each concentration level should be within ±15% of their respective nominal value 
except at LLOQ QC where it must be within  20 % of the nominal value.
1.13. SAFETY PRECAUTIONS
Always wear protective clothing, particularly disposable gloves and masks during handling 
of drug   samples. Gloves should be removed in such a way that the skin does not come into contact 
with external surface of the glove.
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If biological matrix is spilled, it should be cleaned up immediately with 4% hypochlorite solution. 
Hands should be washed with soap and water before leaving the laboratory or whenever 
contaminated. Broken glassware should not be handled directly by hand. Pick up by mechanical 
means such as brush, dustpan, tongs or forceps.
1.14. DATA PROCESSING
              The chromatograms were acquired using the computer based Analyst 1.4.2 software.  The 
data was processed by peak area ratio method using same software.  The concentration of the 
unknown was calculated from the following equation using regression analysis of spiked calibration 
of standard with the reciprocal of the square of the drug to internal standard concentration ratio as a 
weighting factor [1/(concentration ratio) 2].
                                 y = mx + c
Where,                        y = peak area ratio of Naproxen to internal standard 
m = slope of the calibration curve
x = concentration ratio of Naproxen to internal standard
c = y-axis intercept of the calibration curve.
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AIM AND OBJECTIVE
AIM:
         The aim of this study is to develop and validate a specific bioanalytical method by LC-
MS/MS for the estimation of Alosetron in K2EDTA human plasma using Alosetron D3 as internal 
standard 
OBJECTIVE:
         Methods of measuring drugs in biological media are increasingly important due to problems 
related to bioavailability and bioequivalence, new drug development, drug abuse, clinical 
pharmacokinetics, and drug research are highly dependent on accurately measured drugs in 
biological samples.
For the estimation of the drugs present in the biological fluid, LCMS/MS method is 
consider to be more suitable since this is a powerful and rugged method. It is also extremely 
specific, linear, precise, accurate, sensitive and rapid.
Currently there is a need in the pharmaceutical environment to develop Bio-analytical 
methods for the determination of Alosetron in human plasma. The developed method could then be 
applied to clinical trials to obtain accurate pharmacokinetic parameters in human plasma.
Already HPLC-UV, LC-MS / MS, and GC-MS methods have been reported for Alosetron 
in various Biological media. Some of these methods use complicated extraction instruments, long 
and tedious extraction procedures, and large amounts of solvents or biological fluids for extraction 
while other methods have a long turnaround time during analysis
The main objective of this work is to develop rapid, selective and sensitive HPLC-UV and 
LC-MS / MS methods that have short and simple extraction procedures, consume small amounts of 
solvent and biological fluid for extraction and a short turn-around time.
1. Litrature survey
a) Alosetron – category, molecular formula, molecular weight, chemistry, Physiochemical 
properties, pharamacological & pharmaceutical properties.
b) Search for analytical methods if any (HPLC, LCMS/MS)
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2. Method Development
 Stock solution preparation and tunning of analyte., 
 Optimization of chromatographic conditions were proposed to be developed and optimized , 
 Selection of Mass range,
 Selection of initial separation conditions,
 Nature of the stationary phase,
 Nature of the mobile phase (pH, peak modifier, solvent strength, ratio and flow rate),
 Sensitivity and
 Selection of internal standard.
3. Validation of Bioanalytical method as per Guidelines
The developed method were also proposed to be validated using the various validation 
parameters such as,
 Accuracy,
 Precision,
 Selectivity,
 Sensitivity
 Linearity and Range,
 Matrix effect,
 Carryover,
 Recovery,
 Dilution Integrity,
 Robustness / ruggedness,
 Stability and
 System suitability.
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LITERATURE REVIEW
3.1 Ismail IM et al., (2005) reported metabolism of radiolabelled alosetron was studied in rat, dog, 
rabbit, mouse and human. The metabolism in rat and dog was studied at a low and an elevated dose 
designed to generate sufficient quantities of metabolite for definitive identification. A strategy for 
the characterization of metabolites in cases of extensive metabolism was developed and 
demonstrated for alosetron. Semi-preparative high-performance liquid chromatography (HPLC), 
liquid chromatography-mass spectrometry (LC-MS), nuclear magnetic resonance (NMR) and liquid 
chromatography-nuclear magnetic resonance (HPLC-NMR) enabled the isolation and 
characterization of 28 metabolites of alosetron. The characterization of the metabolites in animal 
excreta facilitated the identification of human systemic metabolites.
3.2 Thomas L. Lloyd et al., (1996) reported method of analysis for the determination of alosetron 
in human plasma or serum has been developed. The method was fully automated using a laboratory 
robot in order to improve analytical precision, efficiency and safety. The assay involved solid-phase 
extraction with reversed-phase HPLC separation and fluorescence detection. A validation exercise 
over the concentration range of 0.1 to 20 ng/ml demonstrated the selectivity, linearity, sensitivity, 
accuracy, precision, extraction efficiency, ruggedness and stability of the method. The method has 
been applied in support of numerous human pharmacokinetic/biopharmaceutic studies over the last 
five years.
3.3 Wring SA et al., (1994) reported the development of a radioimmunoassay (RIA) for the sub-ng 
ml-1 determination of alosetron, a potent and selective 5HT3 receptor antagonist, in human urine 
and saliva is described. The antiserum was raised in Soay sheep following primary and booster 
immunizations with an immunogen prepared by conjugating alosetron-p-azobenzoic acid to bovine 
serum albumin (BSA). The radioligand consisted of alosetron specifically 125-iodinated on the 2-
position of the imidazole group. The mean (+/- standard deviation) theoretical sensitivity (minimum 
detectable dose corresponding to the imprecision of the zero standard) of the RIA is 3.2 +/- 2.6 pg 
ml-1 (n = 12) of alosetron in assay diluent (0.1% m/v gelatine-0.05% m/v sodium azide in 0.1 mol 
l-1 phosphate buffer solution, pH 7.4). The working calibration range using 0.1 ml samples of 
saliva and 20-fold diluted urine is 0.10-6.40 ng ml-1 of alosetron. Urine samples were diluted prior 
to assay to overcome adverse matrix effects; consequently, the lower limit of quantification for 
undiluted urine is 2.0 ng ml-1 of alosetron. Inter- and intra-assay bias and imprecision over the 
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working calibration range were generally < +/- 12% and < 13%, respectively, except at the 0.10 ng 
ml-1 alosetron level, where the corresponding values were < +/- 17.3% and < 20.2%. The antiserum 
was free from adverse cross-reactivity with either a synthetic precursor of alosetron or with four 
major metabolites of the drug.
3.4 Lloyd TL et al., (1996) reported a method of analysis for the determination of alosetron in 
human plasma or serum has been developed. The method was fully automated using a laboratory 
robot in order to improve analytical precision, efficiency and safety. The assay involved solid-phase 
extraction with reversed-phase HPLC separation and fluorescence detection. A validation exercise 
over the concentration range of 0.1 to 20 ng/ml demonstrated the selectivity, linearity, sensitivity, 
accuracy, precision, extraction efficiency, ruggedness and stability of the method. The method has 
been applied in support of numerous human pharmacokinetic/biopharmaceutic studies over the last 
five years.
3.5 Koch K.M et al., (2004) reported to assess the pharmacokinetics of alosetron, its effect on in 
vivo enzyme activities, and influence of demographic factors during repeated dosing.
Methods: Thirty healthy men and women received 1 mg oral alosetron twice-daily for 29.5 days 
and a single oral dose of a metabolic probe cocktail before and on the last day of alosetron dosing. 
Serum alosetron concen-trations were measured on days 1, 8, 15, 22 and 29. Probe-substrate and 
metabolite concentrations were measured after each cocktail dose.
3.6 Camilleri M, Northcutt AR, Kong S, et al., (2000) Efficacy and safety of alosetron in women 
with irritable bowel syndrome: a rand-omised, placebo-controlled trial. Lancet 2000; 355: 1035–40. 
3.7 Koch KM, Palmer JL, Noordin N, et al., (2002) reported the Sex and age differences in the 
pharmacokinetics of alosetron. Br J Clin Pharmacol 2002; 53: 238–42. 
3.8 Gupta SK, Gooding A.E, Alianti JR et al., (1996) reported the determination of alosetron in 
human plasma or serum by high-performance liquid chromatography with robotic sample 
preparation. J Chromatogr B: Biomed Appl 1996; 678: 261–7.
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4.1 ALOSETRON HYDROCHLORIDE
Chemical IUPAC Name:
2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one, 
monohydrochloride.
Empirical formula: C17H18N4O•HCl
Molecular Weight: 330.8 g/mol(salt form)
                                 294.32 g/mol(free form)                          
Chemical structure:
DESCRIPTION:
ALOSETRON is a potent and selective antagonist of the serotonin 5-HT3 receptor type. 
Chemically, alosetron is designated as 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-
yl)methyl]-1H-pyrido[4,3-b]indol-1-one, monohydrochloride. 
Physio-chemical Properties:
ALOSETRON is a white to beige solid that has a solubility of 61 mg/mL in water, 42 mg/mL in 
0.1M hydrochloric acid, 0.3 mg/mL in pH 6 phosphate buffer, and < 0.1 mg/mL in pH 8 phosphate 
buffer.
pKa value: It has a pKa 13.32.
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Protine Binding: 82%
Bioavailability: 50% - 60%
Partition Coefficient: 1.61
Half-life: 1.5-1.7 hours
Mechanism of Action:
Alosetron has an antagonist action on the 5-HT3 receptors of the enteric nervous system of
the gastrointestinal tract. While being a 5-HT3 antagonist like ondansetron, it is not classified or 
approved as an antiemetic. Since stimulation of 5-HT3 receptors is positively correlated with 
gastrointestinal motility, alosetron's 5-HT3 antagonism slows the movement of fecal matter through 
the large intestine, increasing the extent to which water is absorbed, and decreasing the moisture 
and volume of the remaining waste products.
Pharmacology:
            ALOSETRON is a quinolone/fluoroquinolone antibiotic. ALOSETRON is bactericidal and 
its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme 
called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into 
two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. 
ALOSETRON is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-
negative bacteria.
Absorption:
ALOSETRON is rapidly absorbed after oral administration with a mean absolute bioavailability of 
approximately 50% to 60% (approximate range 30% to > 90%). After administration of 
radiolabeled alosetron, only 1% of the dose was recovered in the feces as unchanged drug. 
Following oral administration of a 1-mg alosetron dose to young men, a peak plasma concentration 
of approximately 5ng/mL occurs at 1 hour. In young women, the mean peak plasma concentration 
is approximately 9ng/mL, with a similar time to peak.
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Side Effects: 
Common side effects of ALOSETRON are constipation, abdominal discomfort and pain. 
Less common side effects of ALOSETRON are nausea, gastrointestinal discomfort and pain, 
abdominal distention, regurgitation and reflux, hemorrhoids direction.
Indication:
ALOSETRON is indicated only for women with severe diarrhea-predominant irritable 
bowel syndrome. 
Storage:
Keep tightly closed. Store at 2-8 C.
4.2. ALOSETRON D3 (Internal standard)
Chemical IUPAC Name:
2, 3, 4, 5-Tetrahydro-5-(methyl-d3)-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1H-pyrido[4,3-b]indol-
1-one Hydrochloride
Empirical formula: C17H16D3ClN4O
Molecular Weight: 331.34 g/mol
Chemical structure:
pKa value: It has a pKa 14.044
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MATERIALS & METHODS
  MATERIALS
The method requires the following standards, equipments, reagents and biological matrix. 
Note: The standards, equipments, reagents from different manufacturers, with an equivalent 
specification may be used. Weights, volume mentioned can be scaled up/scaled down based 
on requirement.
5.1 Analyte Standard
Use authenticated Alosetron reference/working standards for preparation of standard stock 
solution.
5.1.1 Internal Standard
Use authenticated Alosetron D3 reference/working standards for preparation of internal 
standard stock solution.
5.2.1 Equipments
Equipment Make/ Models
LC-MS/MS Waters TQ MS
UPLC Waters Acquity UPLC
Precision balances Mettler Toledo XP205, XP2U
Auto pipettes Eppendorf
Column Waters X Bridge BEH Phenyl, 2.5 µm (50 x 2.1 mm)
Vortex mixer Velp
Plate form Shaker Heidolph
Centrifuge Eppendorf
Sonicator Bandelin sonorex
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Deep Freezer (-70oC) New Brunswick scientific
Deep Freezer (-20oC) Bio Care
Refrigerator Samsung
5.2.2    Reagents, Chemicals, Solvents and materials
Reagent/Chemical Brand Purity/Grade
Acetonitrile Fischer Scientific HPLC
Methanol J.T Baker HPLC
Ammonia Merck GR
Water Rankem HPLC
Volumetric flasks Borosil A
Eppendrof tubes Tarsons -
RIA vials Tarsons -
Tips Tarsons -
Multitips Eppendorf -
Reagent bottles Borosil -
Biological matrix
Use screened interference free human K2EDTA plasma for preparation of calibration 
standards and quality control samples.
5.3.1 PREPARATION OF SOLUTIONS
Preparation of Diluent [Acetonitrile: Water (10:90% v/v)]
Transfer 900 mL of Water and 100 mL of Acetonitrile in to 1000 mL reagent bottle and 
shake well, sonicate and label the solution.
Preparation of Buffer [0.1% v/v Ammonia in water]
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Transfer 999 mL of water into 1000 mL reagent bottle and add 1 mL of Ammonia solution. 
Shake well, sonicate and label the solution.
Preparation of Strong Needle Wash [(Acetonitrile: Water (80:20% v/v)]
Transfer about 800 mL of Acetonitrile and 200 mL of water in to 1000 mL reagent bottle, 
shake well, sonicate and label the solution.
Preparation of Weak Needle Wash [(Acetonitrile: Water: Ammonia (50:50:0.2% v/v)]
Transfer about 500 mL of Acetonitrile and 500 mL of water in to 1000 mL reagent bottle 
and add 2 ml of Ammonia solution, shake well, sonicate and label the solution.
Preparation of Seal Wash [(Water: Methanol (95:5% v/v)]
Transfer about 950 mL of water and 50 mL of methanol in to 1000 mL reagent bottle, shake 
well, sonicate and label the solution.
Preparation of Aqueous standard
Transfer 0.033 mL of spiking solution SS-MQC in to RIA vial and add 0.417 mL of internal 
standard dilution. Then add 9.550 mL of Diluent. Prepare the aqueous standard as and when 
required used for system suitability and analytical batch.
Note: As per the requirement, volume of the solutions required can be altered keeping the 
concentration/composition same.
5.3.2 PREPARATION OF STANDARD SOLUTIONS
Analyte stock solution (w/v) (Alosetron 100.000 µg/mL)
Weigh and transfer about 5.0 mg of Alosetron in to 50 mL volumetric flask. Dissolve with 5 
mL of Diluent and make up the volume with the same. Calculate the final concentration by 
considering its potency, salt and actual amount weighed. Label and store in refrigerator (2ºC 
to 8ºC). Separate Weighing should be done for Calibration Standards and QC Samples and 
label the solution.
Internal Standard stock solution (w/v) (Alosetron D3 100.000 µg/mL)
Weigh and transfer about 2.0 mg of Alosetron D3 in to 20 mL volumetric flask. Dissolve 
with 5mL of acetonitrile and make up the volume with the same. Calculate the final 
concentration by considering its potency and actual amount weighed. Label as ISA and store 
in refrigerator (2ºC to 8ºC).
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Internal Standard dilution (w/v) (0.050µg/mL ISTD) 
Transfer 0.200 mL of internal standard stock in to 2 ml volumetric flask and make up the 
volume with diluent. And then transfer 0.250 mL into 50 mL volumetric flask and make up 
the volume with diluent. Label and shall be stored in refrigerator (2ºC to 8ºC).
Preparation of Calibration Standards
Preparation of Calibration Standard spiking solutions for Analyte (Alosetron)
Prepare spiking solutions of calibration standard (CS) from serially diluted solutions using 
diluent as per the table given below. Store the spiking solutions of CS samples in 
refrigerator at (2ºC to 8ºC)
Solution 
ID
Conc.
(µg/mL)
Vol. 
Taken 
(mL)
Vol. of 
diluent
(mL)
Total 
Vol.(mL
)
Conc.
(µg/mL)
CS Spiking 
Solution ID
ANA 89.2097 1.000 4.000 5.000 17.8419 ANA-IMA01
ANA-
IMA01
17.8419 0.400 4.600 5.000 1.4274 SS-08
SS-08 1.4274 4.050 0.950 5.000 1.1562 SS-07
SS-07 1.1562 3.750 1.250 5.000 0.8672 SS-06
SS-06 0.8672 3.380 1.620 5.000 0.5862 SS-05
SS-05 0.5862 2.500 2.500 5.000 0.2931 SS-04
SS-04 0.2931 0.510 4.490 5.000 0.0299 SS-03
SS-03 0.0299 2.500 2.500 5.000 0.0150 SS-02
SS-02 0.0150 2.500 2.500 5.000 0.0075 SS-01
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Preparation of Spiked plasma Calibration Standards
Prepare CS by spiking CS spiking solution in screened human K2EDTA plasma as per the 
table given below. Label and store in deep freezer (-70± 20 ºC)
Spiking 
solution 
ID
Conc.
(µg / mL)
Vol.
(mL)
Vol. of 
Matrix.
(mL)
Final Vol.
(mL)
Final Conc.
(ng/ mL)
CS ID
SS-01 0.0075 0.040 1.960 2.000 0.150 CS01
SS-02 0.0150 0.040 1.960 2.000 0.300 CS02
SS-03 0.0299 0.040 1.960 2.000 0.598 CS03
SS-04 0.2931 0.040 1.960 2.000 5.862 CS04
SS-05 0.5862 0.040 1.960 2.000 11.724 CS05
SS-06 0.8672 0.040 1.960 2.000 17.344 CS06
SS-07 1.1562 0.040 1.960 2.000 23.124 CS07
SS-08 1.4274 0.040 1.960 2.000 28.548 CS08
5.4 Preparation of Quality Control Samples
5.4.1 Preparation of QC spiking solutions for Analyte (Alosetron)
Prepare spiking solutions of QC from serially diluted solutions using diluent as per the table 
given below. Store the spiking solutions of QC samples in refrigerator at (2ºC to 8ºC).
Solution 
ID
Conc.
(µg/mL)
Vol.Take
n (mL)
Vol. of 
diluent
(mL)
Total 
Vol.(mL)
Final 
Conc. 
(µg/mL)
QC Spiking 
Solution ID
ANA 89.2231 1.000 4.000 5.000 17.8446
ANA-
IMA01
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ANA-
IMA01
17.8446 0.580 9.420 10.000 1.0350 SS-HQC
SS-HQC 1.0350 2.350 2.650 5.000 0.4541 SS-MQC
SS-MQC 0.4541 1.800 3.200 5.000 0.1635 SS-IMQC
SS-
IMQC
0.1635 0.680 4.320 5.000 0.0222 SS-LQC
SS-LQC 0.0222 1.700 3.300 5.000 0.0076 SS-LLOQC
5.4.2 Preparation of spiked plasma QC samples 
Prepare QC standards by spiking QC spiking solution in screened human K2EDTA plasma 
as per the table given below. Label and store in deep freezer (-70± 20 ºC).
Spiking 
solution ID
Conc.
(µg/ mL)
Vol. of 
Spiking 
Solution 
(mL)
Vol. of 
Matrix.
(mL)
Final Vol.
(mL)
Final Conc.
(ng/ mL)
QC ID
SS-LLOQC 0.0076 0.040 1.960 2.000 0.151 LLOQC
SS-LQC 0.0222 0.040 1.960 2.000 0.445 LQC
SS-IMQC 0.1635 0.040 1.960 2.000 3.270 IMQC
SS-MQC 0.4541 0.040 1.960 2.000 9.082 MQC
SS-HQC 1.0350 0.040 1.960 2.000 20.700 HQC
Aliquot approximately 0.300 ml of each CS and QC sample into pre-labeled polypropylene 
tubes and cap them tightly. Aliquot 0.500 ml of pooled plasma into pre-labeled 
polypropylene tubes for standard blank and standard zero samples separately. Store CS, QC 
samples, standard blank and standard zero samples in deep freezer at -70± 20 ºC and -
20±5ºC for freeze thaw and Long term stability samples.
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5.5 CALIBRATION AND CALCULATIONS
Software used :
       
Mass Lynx  Version 4.1
Weighting factor : Linear, 1/X2.
Analysis mode :
        
  Peak area ratio (Analyte to ISTD) and concentration 
of              Analyte 
Calculation :   Using following equation by Mass lynx Version 4.1
y = m x + c, 
Where, 
x = Concentration of Analyte in ng/ml
y = Peak area ratio of analyte to ISTD 
m = Slope of calibration Curve
c = Intercept on Y- axis
5.6 INSTRUMENTAL PARAMETERS:
5.6.1 METHOD DEVELOPMENT OF ALOSETRON
Method development is a trial and error process. It consists of various steps. Generally it 
starts with tuning of Alosetron.
5.6.2Tuning of analyte (Alosetron)
Finally stock solution of Alosetron was prepared and diluted to 500ng/ml. This stock dilution was 
infused in full scan mode. Then from the result, m/z of parent ion was selected. Molecular weight
of Alosetron is 294.18 so, m/z peak of 295.18 selected as a parent ion, as we are using positive 
mode. 
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Then for fragmentation of parent ion, infused the stock dilution in product ion mode and 
checked for m/z of various daughter ions obtained. Prominent and suitable daughter ion selected by 
altering various parameters,
For ex:- Compound dependent parameters:- DP,FP,EP,CE,CXP,CEP
  Source dependent parameters:- Nebulizer gas, curtain Gas-2, Temperature
                                                     and Ion spray voltage.
It was found that m/z of 295.18 shows a good and stable response. So it selected as daughter ion. 
Re-optimize the parameters. Finally the parameter selected when the selected daughter ion shows 
maximum stable response. Then infused stock dilution using m/z of selected parent and daughter 
ion in Multiple Reaction Monitoring(MRM) mode. Re-optimized the parameters by injecting drug 
in mobile phase.
5.6.3. TRAIL ON COLUMN AND MOBILE PHASE:
The trails were conducted using different column and by changing the mobile phase 
composition.
Trail 1
In this trail Ascentis Phenyl column, 3µm (5x4.6mm) and mobile phase of 5mM 
Ammonium Formate with 0.1% Formic Acid: ACN (30:70) was used.
Trail 2
In this trail Phenomenex Phenyl Hexyl column was used with a Mobile Phase of 5mM 
Ammonium Acetate with 0.1% Formic Acid: ACN (30:70) was used.
Trail 3
In this trail Ascentis Phenyl column, 3µm (5x4.6mm) was used with a Mobile Phase of 
5mM Ammonium Acetate with 0.1% Formic Acid: ACN (30:70) was used.
Conclusion:
In trail 1 peak shape was not good, as it showing tailing. Also the response was less.
In trail 2 peak shape was quite good, as it showing little tailing. Also the response was more 
as compared with trail 1.
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In trail 3 peak shape and response were maximum and stable.
5.6.4. TRIAL ON EXTRACTION PROCEDURE:
In the method Development first step is on extraction techniques. For that different 
extraction methods were tried as shown below.
BY LIQUID-LIQUID EXTRACTION (LLE)
Trail 01:
Procedure:
Withdraw the spiked plasma samples from the deep freezer and allow them to thaw at room 
temperature. Aliquot 0.100ml into a clean RIA vial and add 50 µl of Internal Standard (10µg/ml). 
Vortex well and mix well. Add 2.5ml of TBME and vibramax for 10 minutes. Centrifuge the 
sample at 4500rpm for 10 minutes at 4ºC. Collect the supernatant of 2.0ml and evaporate till 
dryness. Reconstitute the residue with 0.500ml of mobile phase and inject 10 µl into LCMS/MS.
Conclusion:
Improper peak shape was observed.
Trail 02:
Procedure:
Withdraw the spiked plasma samples from the deep freezer and allow them to thaw at room 
temperature. Aliquot 0.100ml into a clean RIA vial and add 50 µl of Internal Standard (10µg/ml). 
Vortex well and mix well. Add 2.5ml of Dichloromethane: Diethylether (30:70) and vibramax for 
10 minutes. Centrifuge the sample at 4500rpm for 10 minutes at 4ºC. Collect the supernatant of 
2.0ml and evaporate till dryness. Reconstitute the residue with 0.250ml of mobile phase and inject 
10 µl into LCMS/MS.
Conclusion:
Fluctuation in response was observed.
Trail 03:
Procedure:
Withdraw the spiked plasma samples from the deep freezer and allow them to thaw at room 
temperature. Aliquot 0.100ml into a clean RIA vial and add 50 µl of Internal Standard (10µg/ml). 
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Vortex well and mix well. Add 2.5ml of Ethyl Acetate and vibramax for 10 minutes. Centrifuge the 
sample at 4500rpm for 10 minutes at 4ºC. Collect the supernatant of 2.0ml and evaporate till 
dryness. Reconstitute the residue with 0.250ml of mobile phase and inject 10 µl into LCMS/MS.
Conclusion:
Less response with Irrespective peaks shape was observed.
BY PROTEIN PRECIPITATION EXTRACTION METHOD
Trial 04:
Procedure:
Procedure
Withdraw the spiked plasma samples from the deep freezer and allow them to thaw at room 
temperature. Aliquot 0.200ml into a clean RIA vial and add 50 µl of Internal Standard (1µg/ml). 
Vortex well and mix well. Add 0.600ml of Methanol Vibramax for 10 minutes. Centrifuge the 
sample at 13000rpm for 5 minutes at 4ºC. Add 0.200ml of supernatant solution with 0.400ml of 
mobile phase and vortex. Inject 10 µl into LCMS/MS.
Conclusion:
Less response with Irrespective peaks shape was observed.
Trail 05:
Procedure
Withdraw the spiked plasma samples from the deep freezer and allow them to thaw at room 
temperature. Aliquot 0.200ml into a clean RIA vial and add 50 µl of Internal Standard (1µg/ml). 
Vortex well and mix well. Add 0.600ml of ACN Vibramax for 10 minutes. Centrifuge the sample 
at 13000rpm for 5 minutes at 4ºC. Add 0.200ml of supernatant solution with 0.400ml of mobile 
phase and vortex. Inject 10 µl into LCMS/MS.
Conclusion:
           Good peak Shape and Constant in response were observed.
5.6.5. PERFORMANCE CHECKING OF SELECTED METHOD
In order to check the performance of selected method, three precision and accuracy batch 
was processed and evaluated the results for meeting acceptance criteria.
57
A trail precision and accuracy batch consists of,
-AQS MQC
-RS
-Blank
-Blank along with Internal Standard
-Standards CC1 –CC8
-Six set of QCs
5.7. SAMPLE PROCESSING
             1. Ensure that the subdued (yellow) light is on.
2. Retrieve the standard blank, standard zero, CS set and QC samples from the deep 
freezer and thaw the samples at room temperature. 
       3. Process all the samples under monochromatic light
4. Homogenize the sample by vortex mixing.
5. Add 50 µL of internal standard (0.050µg/mL Alosetron D3) in to all labelled 
Eppendorf tubes, except Blank.
6. Transfer 200µL of sample in to the corresponding labelled Eppendorf tubes.
7. Add 600µL of Acetonitrile and vortex.
8. Centrifuge the samples at 13000 rpm at 4°C for 10 minutes.
9. Transfer 0.200 mL of supernatant in to labelled polypropylene RIA vials.
10. Add 0.400 mL of Diluent and vortex the solution.
11. Transfer the samples in to Auto sampler vials.
12. Load the samples into LCMS/MS.
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5.8. CHROMATOGRAPHIC CONDITIONS
LC Conditions
Mobile phase & Gradient 
program
Pump A: Acetonitrile
Pump B: Buffer (0.1% Ammonia in water)
Time Flow rate ( mL/min)
% Ratio
Pump A Pump B
Initial 0.400 30 70
0.30 0.400 30 70
0.60 0.400 50 50
0.80 0.400 90 10
1.30 0.400 90 10
1.50 0.400 30 70
2.00 0.400 30 70
Injection volume 10  µL 
Retention time
Alosetron:  0.80 ± 0.500 min.
ISTD:  0.80 ± 0.500 min.
Column oven temperature 40 ±5°C
Auto sampler temperature 5 ± 3°C 
Run time 2.0 min 
Strong Needle wash Acetonitrile: Water (80:20 % v/v)
Weak Needle wash Acetonitrile: Water: Ammonia (50:50:0.2% v/v)
Seal wash Methanol: Water (5:95 % v/v)
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Mass Parameters*
Capillary voltage 0.5 kv
Desolvation Temperature 550 oC
Desolvation Gas Flow 1100 L/hr
Cone Gas Flow 50 L/hr
Collision Gas Flow 0.15  mL/min
Acquisition*
Parameters Alosetron ISTD 
Transition 295.13/201.09 (m/z) 298.10/204.07 (m/z)
Polarity Positive Positive
MS1 resolution Unit Unit
MS2 resolution Unit Unit
Dwell time (sec) 0.100 0.100
Cone Voltage 24 24
Collision energy 16 16
Instrumentation
Detector Waters XEVO TQ Triple Quad LC/MS
Ion source ESI+
Pump Waters Acquity Binary Solvent Manager
Auto sampler Waters Acquity Sample Manager
Column oven Waters Acquity
Column Waters X Bridge BEH Phenyl, 2.5 µm (50 x 2.1 mm)
          *Mass spectrometer parameters may differ slightly between instruments
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Sample Processing Check List
MV No:                                                          Batch ID:           
Date:                               
S.No. Procedure Y/N Initial
1 Ensure that the subdued (yellow) light is on.
2
Retrieve the standard blank, Standard zero, CS set, QC samples 
from the deep freezer.  Process all the samples under 
monochromatic light.
3 Thaw the samples at room temperature.
4 Homogenize the sample by vortex mixing.
5
Add 50 µL of internal standard (0.050µg/mL Alosetron D3) in to 
all labelled Eppendorf tubes, except Blank.
6
Transfer 200 µL of sample in to the corresponding labelled 
Eppendorf tubes.
7 Add 600 µL of Acetonitrile and vortex.
8 Centrifuge the samples at 13000 rpm at 4°C for 10 minutes
9
Transfer 0.200 mL of supernatant in to labelled polypropylene RIA 
vials.
10 Add 0.400 mL of Diluent and vortex the solution.
11 Transfer the samples in to Auto sampler vials.
12 Load the samples into LCMS/MS.
Remarks: Verified by:
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RESULTS AND DISCUSSION
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RESULTS AND DISCUSSION
6.1 Chromatography
A typical chromatogram obtained from a processed blank human K2EDTA plasma sample 
is illustrated in Figure 1. Representative chromatograms of the lower limit of quality 
control, low, intermediate, medium and high quality control (QC) and upper limit of 
quantification samples are displayed in Figures 1, 2, 3,4,5,6 & 7 respectively.
The retention times of Alosetron and internal standard are approximately 0.80 and 0.79 
minutes, respectively. The overall chromatography time is 2 minutes.
6.2 Selectivity
Selectivity was evaluated by analyzing thirteen different human K2EDTA plasma lots 
(eleven normal lots and one Haemolysed and one Lipemic lot) obtained from thirteen 
independent sources. No significant interference observed at the retention time of analyte 
and internal standard for 12 and 13 lots respectively. Results are presented in Table 1.
Table 1: Selectivity
S. No.
Blank Plasma Lot 
ID
Extracted blank LLOQ % Interference
Area at 
the RT 
of 
Analyte
Area 
at the 
RT of 
IS
Analyte 
Area
IS 
Area
Area at 
the RT of 
Analyte
Area at 
the RT 
of IS
1 MT-113/13_BLK 92 75 1411 66602 6.520 0.113
2 MT-142/13_BLK 52 24 1328 66627 3.916 0.036
3 MT-147/13_BLK 52 14 1311 68625 3.966 0.020
4 MT-150/13_BLK 0 0 1278 67045 0.000 0.000
5 MT-151/13_BLK 62 11 1385 68661 4.477 0.016
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6 MT-152/13_BLK 10 10 735 34134 1.361 0.029
7 MT-154/13_BLK 2356 11 1288 67850 182.919 0.016
8 MT-155/13_BLK 28 0 1207 64490 2.320 0.000
9 MT-156/13_BLK 26 0 1163 63031 2.236 0.000
10 MT-157/13_BLK 13 0 1316 65091 0.988 0.000
11 MT-158/13_BLK 14 0 1144 62285 1.224 0.000
12 MT-153/13(H)_BLK 44 0 1094 61827 4.022 0.000
13 MT-005/12(L)_BLK 125 12 1120 63751 11.161 0.019
6.3 Matrix Effect
Blank plasma samples of thirteen different human K2EDTA plasma (eleven normal lots and 
one Haemolysed and one Lipemic lot) sources were processed and spiked with aqueous low 
quality control and high quality control (post extraction addition) and analyzed in a single 
run along with diluted pure standard at each concentration level. 
Table 2: Matrix Effect
QC ID
Aqueous 
Analyte 
Area 
Ratio
Aqueous 
IS  Area 
ratio
Blank Plasma Lot ID
Post Extracted LQC with IS Matrix Effect
Analyte 
Area Ratio
IS  Area 
Ratio
ME of 
Analyte
ME of IS
IS-
normalized 
MF
LQC
0.048 20.872 LQC_MT-113/13 0.050 20.076 1.042 0.972 1.072
0.047 21.074 LQC_MT-142/13 0.049 20.331 1.021 0.984 1.037
0.048 20.676 LQC_MT-147/13 0.048 20.641 1.000 0.999 1.001
0.048 20.793 LQC_MT-150/13 0.049 20.385 1.021 0.987 1.035
0.049 20.258 LQC_MT-151/13 0.049 20.538 1.021 0.994 1.027
0.049 20.281 LQC_MT-152/13 0.052 19.250 1.083 0.932 1.163
LQC_MT-154/13 0.050 20.111 1.042 0.973 1.070
LQC_MT-155/13 0.050 20.110 1.042 0.973 1.070
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LQC_MT-156/13 0.050 20.000 1.042 0.968 1.076
LQC_MT-157/13 0.048 20.821 1.000 1.008 0.992
LQC_MT-158/13 0.050 20.039 1.042 0.970 1.074
LQC_MT-153/13(H) 0.048 20.663 1.000 1.000 1.000
LQC_MT-005/12(L) 0.048 20.634 1.000 0.999 1.001
AVERAGE 0.048 20.659 AVERAGE 1.027 0.982 1.047
SD 0.001 0.328 SD 0.025 0.020 0.047
% CV 2.08 1.59 % CV 2.43 2.04 4.49
HQC
2.405 0.416 HQC_MT-113/13 2.391 0.418 0.992 1.008 0.984
2.407 0.415 HQC_MT-142/13 2.411 0.415 1.000 0.999 1.001
2.418 0.414 HQC_MT-147/13 2.383 0.420 0.989 1.011 0.978
2.429 0.412 HQC_MT-150/13 2.413 0.414 1.001 0.999 1.003
2.403 0.416 HQC_MT-151/13 2.428 0.412 1.007 0.993 1.015
2.395 0.418 HQC_MT-152/13 2.407 0.415 0.999 1.001 0.998
HQC_MT-154/13 2.429 0.412 1.008 0.992 1.016
HQC_MT-155/13 2.396 0.417 0.994 1.006 0.989
HQC_MT-156/13 2.415 0.414 1.002 0.998 1.004
HQC_MT-157/13 2.429 0.412 1.008 0.992 1.016
HQC_MT-158/13 2.537 0.394 1.053 0.950 1.109
HQC_MT-153/13(H) 2.413 0.414 1.001 0.999 1.003
LQC_MT-005/12(L) 2.404 0.416 0.998 1.002 0.995
AVERAGE 0.615 1.628 AVERAGE 1.004 0.996 1.008
SD 0.004 0.010 SD 0.016 0.015 0.032
% CV 0.65 0.61 % CV 1.59 1.51 3.18
H- Haemolysed, L- Lipemic
The percentage CV of matrix effect for analyte was found to be 2.43 and 1.59 for low and 
high quality control samples respectively. The percentage CV of IS normalized matrix 
factor was found to be 4.49 and 3.18 for low and high quality control samples respectively. 
Results are presented in Table 2.
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6.4 Carry Over Test 
Auto sampler carry over test was performed by injecting an extracted ULOQ standard 
followed by an extracted blank and found that there is no significant carry over in all two 
instruments tested (BA-MS-07 and BA-MS-08). Results were presented in Table 3. 
Table 3: Carryover Test
Instrument ID: BA-MS-07 Instrument ID: BA-MS-08
SAMPLE
Area at the 
retention of 
Analyte
Area at the 
retention of 
IS
Area at the 
retention of 
Analyte
Area at the 
retention of 
IS
Extracted Blank   18 0 94 24
Extracted ULOQ with IS   257577 87549 141321 48418
Reinjection of Extracted Blank   38 11 115 22
Extracted LLOQ with IS   1520 89826 757 45737
% CARRY OVER 1.32 0.01 2.77 0.00
6.5 Weighting Factor of Regression Method
To determine whether to fit the data for the calibration curves by weighted or unweight 
linear regression, the functional dependence of the natural logarithm of standard deviation 
of the analyte/internal standard area ratio on natural logarithm of sample concentration was 
evaluated. The individual data used for the determination of the power of weights for 
human K2 EDTA plasma calibration curves are presented, in Table 4. The weighting factor 
to be used is 1/X2 since the slope (m) of the regression line equals 0.924.
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Table 4: Weighting Factor of Regression Method
Analyte / Internal Standard Response Ratio
     CS ID CS-1 CS-2 CS-3 CS-4 CS-5 CS-6 CS-7 CS-8
Nominal 
Conc.
0.160 0.320 0.620 5.880 11.740 17.360 23.140 28.920
PA 1 0.017 0.041 0.066 0.602 1.18 1.749 2.299 2.92
PA 2 0.017 0.033 0.065 0.599 1.188 1.786 2.291 2.842
PA 4 0.014 0.026 0.052 0.481 0.959 1.432 1.913 2.359
SD 0.002 0.008 0.008 0.069 0.130 0.195 0.221 0.304
Ln (SD)
-
6.3584
-
4.8921
-
4.8523
-
2.67351
-
2.04049 -1.6369
-
1.51148
-
1.19109
Ln( Conc)
-
1.8326
-
1.1394 -0.478 1.77156 2.463 2.85417 3.14156 3.36453
Slope m= 0.924
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Acceptance Criteria:
Un weighted- m < 0.25
1/X – 0.25 < m < 0.75
I/X2 –m > 0.75
6.6 Calibration Curves
Linearity was evaluated using eight different concentrations. Calibration curves were found 
to be consistently accurate and precise over the 0.160 to 28.920 ng/mL calibration range. 
The coefficient of determination (r2) is greater than or equal to 0.9991. Back-calculations 
were made from the calibration curves to determine Alosetron concentrations of each 
calibration standard. Data are presented in Tables 5 and 6. A typical calibration curve is 
presented in Figure 7.
Table 5: Summary of Calibration Curve Parameters
Y = mx+c (1/x2 weighted)
Batch ID Slope Intercept r2
PA 01 0.1013 0.0007 0.9996
PA 02 0.1007 0.0013 0.9996
PA 04 0.0821 0.0003 0.9997
RUG 0.1038 0.0013 0.9991
PBPA 0.0790 0.0005 0.9999
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Table 6: Back-Calculated Standards from Each Calibration Curve
Calibration 
Standard ID
CS 01 CS 02 CS 03 CS 04 CS 05 CS 06 CS 07 CS 08
Nominal 
Concentration 
(ng/mL)
0.160 0.320 0.620 5.880 11.740 17.360 23.140 28.920
Back 
Calculate
d 
Concentra
tion 
(ng/ml)
PA 
01
0.158 R 0.645 5.930 11.639 17.249 22.681 28.804
PA 
02
0.160 0.315 0.632 5.938 11.786 17.728 22.750 28.228
PA 
04
0.162 0.310 0.635 5.854 11.685 17.447 23.316 28.743
RUG 0.156 0.329 0.650 5.816 11.651 17.559 22.580 28.362
PBP
A
0.161 0.314 0.629 5.879 11.808 17.372 23.079 28.777
AVERAGE 0.159 0.317 0.638 5.883 11.714 17.471 22.881 28.583
SD 0.002 0.008 0.009 0.051 0.078 0.183 0.307 0.268
% CV 1.26 2.52 1.41 0.87 0.67 1.05 1.34 0.94
% ACCURACY 99.38 99.06
102.9
0
100.05 99.78 100.64 98.88 98.83
6.7 Between-Run Accuracy and Precision
The between-run accuracy and precision evaluation were assessed by the repeated analysis 
of human K2EDTA plasma samples containing different concentrations of Alosetron on 
separate occasions. A single run consisted of a calibration curve plus 6 replicates of lower 
limit of quantification, low, intermediate, medium and high quality control samples.
The between-run precision in terms of coefficients of variation ranged between 0.66 and 
10.98 %. The between-run accuracy ranged between 98.58 and 108.13 %. Results are 
presented in Table 7.
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Table 7: Between-Run Accuracy and Precision
QC ID LLOQC LQC IMQC MQC HQC
Nominal Concentration 
(ng/ml)
0.160 0.460 3.180 9.100 22.760
Back 
Calculated 
Concentration    
(ng/ml) 
PA01
0.178 0.482 3.179 9.074 22.458
0.186 0.476 3.372 9.054 22.474
0.161 0.481 3.150 9.017 22.451
0.206 0.485 3.210 9.123 22.598
0.229 0.465 3.219 9.078 22.370
0.175 0.475 3.231 9.114 22.543
PA02
0.159 0.480 3.136 9.034 22.554
0.181 0.473 3.184 8.886 22.689
0.162 0.471 3.161 9.682 22.582
0.168 0.478 3.130 9.044 22.419
0.163 0.475 3.161 9.004 22.262
0.154 0.459 3.144 9.001 22.455
PA04
0.160 0.462 3.192 9.034 22.205
0.160 0.456 3.101 9.072 22.199
0.166 0.471 3.191 9.129 22.509
0.164 0.475 3.154 9.038 22.350
0.171 0.486 3.113 8.859 22.546
0.177 0.455 3.133 8.991 22.199
AVERAGE 0.173 0.473 3.176 9.069 22.437
SD 0.019 0.010 0.061 0.169 0.147
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%CV 10.98 2.11 1.92 1.86 0.66
% ACCURACY 108.13 102.83 99.87 99.66 98.58
6.8 Within-Run Accuracy and Precision
Within-run accuracy and precision evaluations were performed by analyzing replicate 
concentrations of Alosetron in human K2EDTA plasma. The run consisted of a calibration 
curve plus a total of 6 replicates of each of the LLOQC, lower, intermediate, medium and 
higher quality control samples.
The within-run precision in terms of coefficients of variation ranged between 0.35 and 
12.70 %. The within-run accuracy ranged between 98.13 and 118.13 %. Results are 
presented in Table 8.
Table 8: Within-Run Accuracy and Precision
QC ID LLOQC LQC IMQC MQC HQC
Nominal Concentration (ng/ml) 0.160 0.460 3.180 9.100 22.760
Back Calculated 
Concentration 
(ng/ml)
PA01
0.178 0.482 3.179 9.074 22.458
0.186 0.476 3.372 9.054 22.474
0.161 0.481 3.150 9.017 22.451
0.206 0.485 3.210 9.123 22.598
0.229 0.465 3.219 9.078 22.370
0.175 0.475 3.231 9.114 22.543
AVERAGE 0.189 0.477 3.227 9.077 22.482
SD 0.024 0.007 0.077 0.039 0.079
%CV 12.70 1.47 2.39 0.43 0.35
% ACCURACY 118.13 103.70 101.48 99.75 98.78
QC ID LLOQC LQC IMQC MQC HQC
71
Nominal Concentration (ng/ml) 0.160 0.460 3.180 9.100 22.760
Back Calculated 
Concentration 
(ng/ml)
PA02
0.159 0.480 3.136 9.034 22.554
0.181 0.473 3.184 8.886 22.689
0.162 0.471 3.161 9.682 22.582
0.168 0.478 3.130 9.044 22.419
0.163 0.475 3.161 9.004 22.262
0.154 0.459 3.144 9.001 22.455
AVERAGE 0.165 0.473 3.153 9.109 22.494
SD 0.009 0.007 0.020 0.287 0.149
%CV 5.45 1.48 0.63 3.15 0.66
% ACCURACY 103.13 102.83 99.15 100.10 98.83
QC ID LLOQC LQC IMQC MQC HQC
Nominal Concentration (ng/ml) 0.160 0.460 3.180 9.100 22.760
Back Calculated 
Concentration 
(ng/ml)
PA04
0.160 0.462 3.192 9.034 22.205
0.160 0.456 3.101 9.072 22.199
0.166 0.471 3.191 9.129 22.509
0.164 0.475 3.154 9.038 22.350
0.171 0.486 3.113 8.859 22.546
0.177 0.455 3.133 8.991 22.199
AVERAGE 0.166 0.468 3.147 9.021 22.335
SD 0.007 0.012 0.039 0.092 0.161
%CV 4.22 2.56 1.24 1.02 0.72
% ACCURACY 103.75 101.74 98.96 99.13 98.13
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6.9 Ruggedness
The ruggedness of the method was assessed by analyzing a precision and accuracy batch 
using a different serial number of column (Serial No.:01113126616013, BA-CL-100) by 
different analyst in different instrument of similar configuration (Instrument ID.: BA-MS-
08).
The precision in terms of coefficients of variation ranged between 0.53 and 2.91 %. The 
accuracy percentages of nominal concentrations ranged between 99.70 and 107.50 %. 
Results are presented in Table 9.
Table 9:  Ruggedness
Instrument ID : BA-MS-08
Column ID : BA-CL-100
Batch ID : RUG
QC ID LLOQC LQC IMQC MQC HQC
Nominal Concentration 
(ng/ml):
0.160 0.460 3.180 9.100 22.760
Back Calculated 
Concentration  of QC 
samples (ng/ml)  :
0.180 0.471 3.185 9.095 22.744
0.176 0.471 3.191 9.322 22.496
0.171 0.475 3.181 8.927 22.766
0.171 0.482 3.180 9.121 22.844
0.169 0.471 3.195 8.979 22.774
0.167 0.456 3.146 8.992 22.567
Mean   : 0.172 0.471 3.180 9.073 22.699
SD   : 0.005 0.009 0.017 0.142 0.135
%CV   : 2.91 1.91 0.53 1.57 0.59
%ACCURACY 107.50 102.39 100.00 99.70 99.73
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6.10 Production Batch Precision and Accuracy
A total number of 145 samples were processed and analyzed in a single batch to simulate 
the production batch; the precision and accuracy of the quality control samples were 
calculated, the precision in terms of coefficients of variation ranged between 1.36 and 3.72 
%. The accuracy ranged between 99.19 and 105.22 %. Results are presented in Table 10.
Table 10: Production Batch Precision and Accuracy
QC ID LQC IMQC MQC HQC
Nominal Concentration 
(ng/ml):
0.460 3.180 9.100 22.760
Back Calculated QC  
concentrations
0.466 3.245 9.152 22.749
0.500 3.213 9.077 22.776
0.536 3.239 9.159 22.693
0.477 3.375 9.118 22.588
0.479 3.197 9.152 22.474
0.469 3.221 9.167 22.437
0.469 3.237 9.078 22.357
0.494 3.197 9.109 23.155
0.475 3.185 9.577 22.378
0.470 3.183 9.086 22.923
0.456 3.204 9.126 22.158
0.476 3.332 8.891 22.077
0.479 3.254 9.140 22.539
0.498 3.154 9.061 22.870
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0.521 3.310 9.237 22.739
0.476 3.412 9.149 22.482
0.490 3.251 9.153 22.406
0.474 3.197 9.170 22.457
0.488 3.217 9.148 22.407
0.488 3.213 9.174 23.283
0.455 3.199 9.517 22.302
0.473 3.200 9.099 23.035
0.475 3.192 9.142 22.077
0.481 3.164 8.979 21.988
0.473 3.242 9.170 22.735
0.496 3.178 9.078 22.905
0.529 3.248 9.174 22.720
0.470 3.411 9.184 22.626
0.480 3.235 9.096 22.287
0.488 3.212 9.172 22.433
0.492 3.224 9.029 22.222
0.481 3.203 9.154 23.118
Mean   : 0.484 3.236 9.147 22.575
SD   : 0.018 0.065 0.124 0.328
%CV   : 3.72 2.01 1.36 1.45
%ACCURACY 105.22 101.76 100.52 99.19
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6.11 Recovery
6.11.1. Recovery of Analyte
Recovery of Alosetron was evaluated by comparing mean analyte responses of six 
processed samples of low, medium and high quality control samples to mean analyte 
responses of diluted pure standard solutions. The mean recovery values were found to be 
77.36%, 74.39% and 75.37% at low, medium and high quality control levels, respectively. 
The global mean recovery was found to be 75.71% with the coefficient of variation 2.00. 
Results are presented in Table 11.
Table 11: Recovery of Analyte
S. No.
LQC MQC HQC
0.460 ng/mL 9.100 ng/mL 22.760 ng/mL
Aqueous 
Analyte 
response
Extracted 
Analyte 
response
Aqueous 
Analyte 
response
Extracted 
Analyte 
response
Aqueous 
Analyte 
response
Extracted 
Analyte 
response
1 5370 4533 115560 86882 282397 210493
2 5837 4537 116186 83934 282548 213754
3 6021 4495 116627 91779 282603 212538
4 5907 4510 115299 86300 282496 213983
5 5960 4553 115520 84556 285429 212263
6 5952 4483 116660 84194 279776 214760
Mean 5841.167 4518.500 115975.333 86274.167 282541.500 212965.167
SD (±) 238.786 26.935 595.831 2947.164 1789.549 1527.533
CV (%) 4.09 0.60 0.51 3.42 0.63 0.72
% Recovery 77.36 74.39 75.37
Mean 
Recovery
75.71
% CV 2.00
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6.11.2. Recovery of Internal standard
Recovery of internal standard, mean internal standard responses of eighteen processed 
samples were compared with mean internal standard responses of eighteen diluted pure 
internal standard injections. Mean recovery value for the internal standard was found to be 
79.34%. Results are presented in Table 12. 
Table 12: Recovery of Internal Standard
Aqueous Area Extracted Area
107839 91363
118455 92868
119980 92380
119089 91356
118488 92718
119814 94470
117514 95423
118062 93713
118745 94060
117858 94675
117085 93177
117892 92811
118015 92674
118714 93550
118347 93460
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6.12 Sensitivity (Lower Limit of Quantification) 
The sensitivity of the assay was determined by calculating the signal-to-noise (S/N) ratio of 
the chromatographic peak of the lowest calibration standard in each validation run 
containing a calibration curve. Sensitivity was considered sufficient if the S/N ratio is at 
least 5.
The lower limit of quantification, i.e. the lowest standard is 0.160 ng/mL, the coefficient of 
variation found to be 1.26 % and the accuracy is 99.38 %. Results were presented in Table 
13.
118243 94780
119613 94680
117739 94969
AVERAGE 117861 93507
SD 2620.755 1194.610
% CV 2.22 1.28
% Recovery of 
IS
79.34
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Table 13: Sensitivity (Lower Limit of Quantification)
Nominal conc.:  0.160 ng/mL
Calculated Conc. 
(ng/mL)
S/N Ratio
PA BATCH ID
PA01 0.158 394.562
PA02 0.160 312.576
RUG 0.156 1190.031
PA04 0.162 184.602
PBPA 0.161 680.612
Mean 0.159
SD 0.002
% CV 1.26
% Accuracy 99.38
6.13 Dilution Integrity
Six replicates of dilution quality control samples (DQC) were respectively diluted two (1/2th
dilution) and four times (1/4th dilution) in human K2EDTA plasma prior to sample 
processing and analysis. The calculated concentrations, including the dilution factor, 
yielded coefficients of variation of 1.12 and 0.48%, for 1/2th and 1/4th, respectively. 
Percentages of nominal concentrations are 99.53 and 98.81%, respectively. Results are 
presented in Table 14.
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Table 14: Dilution Integrity
QC ID
DQC
DQC Concentration:  ng/mL
2T 4T
Concentration (ng/ml) 45.540 45.540
Back Calculated Concentration 
(ng/ml)
44.774 45.347
44.749 44.706
45.891 45.029
45.895 45.071
45.407 44.857
45.232 44.963
AVERAGE 45.325 44.996
SD 0.509 0.217
% CV 1.12 0.48
% ACCURACY 99.53 98.81
6.14 Reinjection Reproducibility
Six replicates of LQC and HQC samples from PA02 batch were re-injected after 15 hours 
21 minutes along with calibration standards, back calculated concentration of QC samples
were calculated using original calibration standards and re-injected calibration standards, 
accuracy and precision of QC samples were calculated and reported. Results were presented 
in Table 15. 
The result shows that the results are reproducible when re-injected the batch as a whole and 
the samples individually. 
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Table 15: Reinjection Reproducibility
PA Batch ID : PA 02
QC ID
Back Calculated 
Concentration with re-
injected Calibration Curve  
(ng/ml)
Back Calculated 
Concentration with 
original Calibration Curve  
(ng/ml)
LQC HQC LQC HQC
Nominal 
Concentration 
(ng/ml)
0.460 22.760 0.460 22.760
0.477 22.379 0.480 22.554
0.464 22.640 0.473 22.689
0.462 22.669 0.471 22.582
0.475 22.523 0.478 22.419
0.471 22.145 0.475 22.262
0.452 22.450 0.459 22.455
AVERAGE 0.467 22.468 0.473 22.494
SD 0.009 0.210 0.007 0.163
%CV 1.93 0.93 1.48 0.72
% ACCURACY 101.52 98.72 102.83 98.83
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6.15 Stability
6.15.1. Auto sampler stability 
Six replicates of Low (LQC) and high (HQC) Quality control samples of Stability-01 Batch 
were retained after sample analysis and kept stored in auto sampler at 5ºC for 21 hours 40 
minutes. Stability samples were analyzed in a single run with freshly spiked calibration 
curve and quality control samples (Comparison Samples- time zero). Concentrations were 
calculated to determine % stability when compared to time zero. Alosetron is found to be 
stable for 21 hours 40 minutes at 5ºC in auto sampler with % stability of 99.79 and 100.14% 
for LQC and HQC respectively. Results are presented in Table 16.
Table 16: Auto Sampler Stability  
Stability Duration :    21 hours 40 minutes at 5ºC
QC ID
Comparison Sample Stability Sample
LQC HQC LQC HQC
Nominal Concentration 
(ng/ml)
0.460 22.760 0.460 22.760
Back Calculated 
Concentration (ng/ml)
0.485 22.284 0.462 22.059
0.478 22.075 0.471 22.263
0.458 23.278 0.469 23.36
0.476 22.981 0.466 22.92
0.495 23.42 0.473 22.287
0.452 22.19 0.498 23.529
AVERAGE 0.474 22.705 0.473 22.736
SD 0.016 0.592 0.013 0.622
%CV 3.38 2.61 2.75 2.74
% ACCURACY 103.04 99.76
% STABILITY 99.79 100.14
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6.15.2. Bench Top Stability (Analyte in Matrix at Room Temperature)
Six replicates of low and high quality control samples were processed after keeping the 
samples at room temperature for approximately 16 hours 25 minutes (Stability Samples) and 
analyzed with freshly spiked calibration curve and quality control samples (Comparison 
Samples). Concentrations were calculated to determine % stability over time. Alosetron is 
found to be stable in human K2EDTA plasma for 16 hours 25 minutes at room temperature 
with % stability of 101.95 and 101.05% for LQC and HQC respectively. Results are 
presented in Table 17. 
Table 17: Bench Top Stability (Analyte in Matrix at Room Temperature)
Stability Duration :    16 hours 25 minutes
QC ID
Comparison Sample Stability Sample
LQC HQC LQC HQC
Nominal Concentration 
(ng/ml)
0.460 22.760 0.460 22.760
Back Calculated 
Concentration (ng/ml)
0.467 21.978 0.475 22.119
0.469 21.885 0.472 22.443
0.449 22.438 0.457 22.692
0.471 22.076 0.489 22.361
0.478 21.942 0.458 22.403
0.436 22.245 0.476 21.943
AVERAGE 0.462 22.094 0.471 22.327
SD 0.016 0.211 0.012 0.262
%CV 3.46 0.96 2.55 1.17
% ACCURACY 100.43 97.07
% STABILITY 101.95 101.05
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6.15.3. Wet Extract Stability at Room Temperature
Six replicates of low and high quality control samples were processed and reconstituted with 
diluent. The samples were transferred into injector vials and kept for 25 hours 45 minutes on 
bench at room temperature. Samples were injected after 25 hours 45 minutes and analyzed 
with freshly spiked calibration curve and quality control samples (Comparison Samples). 
Concentrations were calculated to determine % stability. Processed samples of Alosetron 
are found to be stable for 25 hours 45 minutes at room temperature with a % stability of 
91.06 and 96.48% for LQC and HQC respectively. Results are presented in Table 18.
Table 18: Wet extract stability at Room Temperature
Stability Duration :    25 hours 45 minutes
QC ID
Comparison Sample Stability Sample
LQC HQC LQC HQC
Nominal Concentration (ng/ml) 0.460 22.760 0.460 22.760
Back Calculated Concentration 
(ng/ml)
0.465 23.485 0.403 22.243
0.501 23.453 0.462 21.992
0.479 23.472 0.478 22.124
0.499 23.618 0.444 22.480
0.500 23.376 0.444 22.687
0.508 22.249 0.456 23.214
AVERAGE 0.492 23.276 0.448 22.457
SD 0.016 0.509 0.025 0.447
%CV 3.25 2.19 5.58 1.99
% ACCURACY 106.96 102.27
% STABILITY 91.06 96.48
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6.15.4. Wet Extract Stability at Refrigerator (2-8 ºC)
Six replicates of low and high quality control samples were processed and reconstituted 
with diluent. The samples were transferred into injector vials and kept for 46 hours 44 
minutes in refrigerator. Samples were injected after 46 hours 44 minutes and analyzed with 
freshly spiked calibration curve and quality control samples (Comparison Samples). 
Concentrations were calculated to determine % stability. Processed samples of Alosetron 
are found to be stable for 46 hours 44 minutes in refrigerated condition with% stability of 
95.93 and 95.88% for LQC and HQC respectively. Results are presented in Table 19.
Table 19: Wet Extract Stability in Refrigerator
Stability Duration :    46 hours 44 minutes
QC ID
Comparison Sample Stability Sample
LQC HQC LQC HQC
Nominal Concentration 
(ng/ml)
0.460 22.760 0.460 22.760
Back Calculated 
Concentration (ng/ml)
0.465 23.485 0.476 22.657
0.501 23.453 0.475 22.295
0.479 23.472 0.478 22.346
0.499 23.618 0.476 22.208
0.500 23.376 0.472 22.068
0.508 22.249 0.453 22.320
AVERAGE 0.492 23.276 0.472 22.316
SD 0.016 0.509 0.009 0.195
%CV 3.25 2.19 1.91 0.87
% ACCURACY 106.96 102.27
% STABILITY 95.93 95.88
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6.15.5. Freeze Thaw Stability at -20°C and -70°C
Low and high quality control samples were prepared, aliquoted and frozen at -20 ± 5°C and 
-70 ± 20°C. Six replicates of LQC and HQC samples were processed after four freeze thaw 
cycle in both the temperature (stability samples). Freeze-Thaw samples were analyzed with 
freshly spiked calibration curve and quality control samples (Comparison Samples) in a 
single run.
Alosetron samples stored at -20 ± 5°C were found to be stable in human K2EDTA plasma 
after four freeze-thaw cycles with % stability of 99.79 and 100.50% for LQC and HQC 
respectively.
Alosetron samples stored at -70 ± 20°C were found to be stable in human K2EDTA plasma 
after four freeze-thaw cycles with % stability of 99.79 and 100.54 for LQC and HQC 
respectively. Results are presented in Table 20.
Table 20: Freeze Thaw Stability at -70°C and -20°C
Number of cycles :   Four
QC ID
Comparison Sample
Stability Sample Stability Sample
-70 ± 20°C -20 ± 5°C
LQC HQC LQC HQC LQC HQC
Nominal Concentration 
(ng/ml)
0.460 22.760 0.460 22.760 0.460 22.760
Back Calculated 
Concentration (ng/ml)
0.480 22.231 0.456 22.199 0.478 22.191
0.479 22.112 0.482 22.051 0.482 22.681
0.460 22.699 0.460 22.709 0.468 22.130
0.486 22.274 0.478 22.649 0.456 22.678
0.493 22.118 0.485 22.444 0.494 22.390
0.450 22.454 0.480 22.555 0.464 22.494
AVERAGE 0.475 22.315 0.474 22.435 0.474 22.427
SD 0.016 0.226 0.012 0.260 0.014 0.235
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% CV 3.37 1.01 2.53 1.16 2.95 1.05
% ACCURACY 103.26 98.04 103.04 98.57 103.04 98.54
% STABILITY 99.79 100.54 99.79 100.50
6.15.6. Short Term Stock Solution Stability of Analyte at room temperature
The stock solution (Stock ID. ANA02) of Alosetron was divided in two parts. One portion 
was placed on the bench at room temperature for 20 hours 57 minutes and other portion in 
refrigerator until analysis. MQC level concentration were prepared from stock solution 
placed on the bench at room temperature were compared against the freshly prepared stock 
dilutions at MQC level from other portion stored in the refrigerator. Alosetron was found to 
be stable in diluent (acetonitrile : water, 10:90) for 20 hours 57 minutes at room 
temperature with a % stability of 99.57. Results are presented in Table 21.
Table 21: Short-Term Stock Solution Stability of Analyte
Stability Duration : 20 hrs 57 min at room temperature
STOCK SOLUTION ID.:
ANA 02
Comparison 
sample peak area
Stability sample 
peak area
80265 80447
80664 80515
81080 80741
80192 79438
80157 79613
80385 79931
AVERAGE 80457.167 80114.167
% STABILITY 99.57
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6.15.7. Short Term Stock Solution Stability of Internal Standard at room temperature
The stock solution (Stock ID. ISA01) of Alosetron D3 was divided in two parts. One 
portion was placed on the bench at room temperature for 20 hours 57 minutes and other 
portion in refrigerator until analysis. Internal standard working solution were prepared from 
stock solution placed on the bench at room temperature were compared against the freshly 
prepared stock dilutions at Internal standard working solution level from other portion 
stored in the refrigerator. Alosetron D3 was found to be stable in acetonitrile for 20 hours 
57 minutes at room temperature with a % stability of 99.35. Results are presented in Table 
22.
Table 22:  Short-Term Stock Solution Stability of Internal Standard
Stability Duration : 20 hrs 57 min at room temperature
STOCK SOLUTION ID.:
ISA 01
Comparison 
sample peak area
Stability sample 
peak area
85337 85499
86998 86891
86379 84809
85449 84937
86478 85706
85438 84883
AVERAGE 86013.167 85454.167
% STABILITY 99.35
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6.15.8. Working solution stability in Refrigerator
Alosetron spiking solution (equivalent to LQC and HQC spiking concentrations) and IS 
spiking solution were prepared using diluent (Acetonitrile: Water) and stored in refrigerator 
for 64 hours 56 minutes (Stability Samples).
Stability samples of Alosetron were diluted at approximately concentrations equal to LQC 
and HQC with IS (stability IS) and compared with comparison sample (sample prepared 
using freshly retrieved stock solution of analyte and IS) are analyzed in a single run, 
responses were used to determine % stability over time. 
Alosetron working solution was found to be stable at refrigerator temperature for 64 hours 
56 minutes with a % stability of 98.74 and 99.28 for LQC and HQC respectively. Results 
are presented in Table 23.
Alosetron D3 working solution was found to be stable at refrigerator for 64 hours 56 
minutes with a % stability of 99.26. Results are presented in Table 24.
Table 23: Working Solution Stability of Analyte in Refrigerator
Stability Duration: 64 hours 56 minutes
Comparison 
sample peak 
area (LQC)
Stability sample 
peak area 
(LQC)
Comparison 
sample peak 
area (HQC)
Stability 
sample peak 
area (HQC)
ANALYTE 
AREA
3301 3249 156998 156328
3184 3251 156950 155945
3292 3235 156320 155522
3235 3263 155424 154183
3326 3257 155814 154592
3329 3164 156536 154709
AVERAGE 3277.833 3236.500 156340.333 155213.167
% 
STABILITY
98.74 99.28
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Table 24: Working Solution Stability of IS in Refrigerator
Stability Duration : 64 hours 56 minutes
Comparison 
sample peak 
area
Stability sample 
peak area
IS AREA
79788 80245
80384 80409
81621 80624
81009 80031
80517 79954
80072 80535
79786 79728
80182 79174
80041 78993
80370 78927
79733 78472
79536 78855
AVERAGE 80253.250 79662.250
% STABILITY 99.26
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6.15.9. Working solution stability in Room temperature
Alosetron spiking solution (equivalent to LQC and HQC spiking concentrations) and IS 
spiking solution were prepared using diluent (Acetonitrile: Water) and kept at room 
temperature for 17 hrs 20 minutes (Stability Samples).
Stability samples of Alosetron were diluted at approximately concentrations equal to LQC 
and HQC with IS (stability IS) and compared with comparison sample (sample prepared 
using freshly retrieved stock solution of analyte and IS) are analyzed in a single run, 
responses were used to determine % stability over time.
Alosetron working solution was found to be stable at room temperature for 17 hours 20 
minutes with a % stability of 95.85 and 100.26 for LQC and HQC respectively. Results are 
presented in Table 25.
Alosetron D3 working solution was found to be stable at room temperature for 17 hours 20 
minutes with a % stability of 100.23. Results are presented in Table 26.
Table 25: Working Solution Stability of Analyte in Room Temperature
Stability Duration : 17 hours 20 minutes
Comparison 
sample peak 
area (LQC)
Stability 
sample peak 
area (LQC)
Comparison 
sample peak 
area (HQC)
Stability 
sample peak 
area (HQC)
ANALYTE 
AREA
3486 3340 152382 153467
3527 3214 153205 153627
3422 3278 153510 152985
3342 3308 152675 153508
3303 3228 153787 153344
3447 3308 151300 152274
AVERAGE 3421.167 3279.333 152809.833 153200.833
% STABILITY 95.85 100.26
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Table 26: Working Solution Stability of IS in Room Temperature
Stability Duration : 17 hours 20 minutes
Comparison 
sample peak 
area
Stability 
sample peak 
area
IS AREA
75735 76455
76986 76900
76450 75980
76128 76739
76014 76887
76908 77402
76722 76439
76251 76331
76349 75051
75795 76207
75757 76310
75292 75808
AVERAGE 76198.917 76375.750
% STABILITY 100.23
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6.15.10. Long Term Stock Solution Stability of Analyte in refrigerator
Alosetron stock solution stability in refrigerator was performed at 18th day (Stability 
Samples). Freshly prepared stock solution of Alosetron (Comparison Samples) and stability 
samples were diluted to approximately MQC concentration and analyzed in a single run, 
Analyte responses were used to determine % stability over time. Alosetron was found to be 
stable in diluents (ACN: Water 10:90 % v/v) for 18 days. The % stability of Alosetron at 
18th day was found to be 100.67. Results are presented in Table 27.
Table 27: Long Term Stock Solution Stability of Analyte at 18 days
Storage Condition: Refrigerator (2- 8 ˚C)
    Analyte
Concentration of stability 
sample
Concentration of fresh 
sample
ANA02 90.343 µg/mL 91.058 µg/mL
STOCK SOLUTION ID.: 
ANA02
Fresh Solution 
Area
Stability Solution  Area
83485 83793
84336 83703
83312 82492
83953 83558
84134 84275
82554 83364
AVERAGE 83629.000 83530.833
% STABILITY 100.67
93
6.15.11. Long Term Stock Solution Stability of Internal Standard in refrigerator 
Alosetron D3 stock solution stability in refrigerator was performed at 18
th day (Stability 
Samples). Freshly prepared stock solution of Alosetron D3 (Comparison Samples) and 
stability samples were diluted to approximately same concentration and analyzed in a 
single run, responses were used to determine % stability over time. Alosetron D3 was found 
to be stable in Acetonitrile for 18 days. The % stability of Alosetron D3 at 18
th day was 
found to be 97.99. Results are presented in Table 28. 
Table 28:  Long Term Stock Solution Stability of Internal Standard at 18 days
Storage Condition: Refrigerator (2- 8 ˚C)
Analyte
Concentration of stability 
sample Concentration of fresh sample
ISA-01 101.559 µg/mL 99.889 µg/mL
STOCK SOLUTION ID.: ISA01
Fresh Solution Area
Stability Solution 
Area
110820 110921
112016 111539
111062 109241
111120 110891
111252 110717
109815 110316
AVERAGE 111014.167 110604.167
% STABILITY 97.99
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6.15.12. Long Term Stability of Analyte in Matrix at -20°C and -70°C
Long term stability of analyte in K2EDTA plasma was performed by using six replicates of 
LQC and HQC samples stored at -20°C and -70°C on 17th days of storage (Stability 
Samples) The samples were analysed with freshly prepared calibration standards and 
quality control samples (Comparison Samples). Alosetron back calculated concentrations 
were used to determine % stability over time. Alosetron was found to be stable in plasma 
for 17 days at -20°C and -70°C.
The % Stability of Alosetron in K2EDTA plasma after 17 days of storage at -20°C and -
70°C was found to be 112.14, 108.90 for LQC, 96.38 and 96.59 for HQC samples 
respectively. Results are presented in Table 29.
Table 29 : Long -Term Stability of Analyte in Matrix at 17 days
Standard
CS 
01
CS 
02
CS 
03
CS 
04
CS 
05
CS 
06
CS 
07
CS 
08
Slope Intercept r2
Nominal 
Conc.(ng/ml)
0.160 0.320 0.620 5.820 11.640 17.220 22.960 28.700
0.0812 -0.0005
0.999
7
Back Calc.Conc. 
(ng/ml):
0.159 0.327 0.611 5.939 11.575 17.279 22.934 28.212
% 
ACCURACY
99.28 102.08 98.63 102.05 99.44 100.34 99.89 98.30
QC ID
Comparison 
Sample
Stability Sample
-70 ˚C -20 ˚C
LQC HQC LQC HQC LQC HQC
Nominal Concentration 
(ng/ml)
0.460 22.580 0.460 22.760 0.460 22.760
Back Calculated 
Concentration (ng/ml)
0.427 22.988 0.478 22.087 0.462 22.377
0.440 22.937 0.479 22.412 0.481 22.456
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0.434 22.912 0.473 22.557 0.467 22.269
0.439 22.982 0.458 22.247 0.463 22.283
0.454 23.280 0.479 22.827 0.605 22.832
0.436 23.149 0.493 22.467 0.469 22.090
AVERAGE 0.438 23.041 0.477 22.433 0.491 22.385
SD 0.009 0.143 0.011 0.256 0.056 0.250
% CV 2.05 0.62 2.31 1.14 11.41 1.12
% ACCURACY 95.22 102.04 103.70 98.56 106.74 98.35
% STABILITY 108.90 96.59 112.10 96.38
6.15.13. Stability of Analyte in Blood
Stability of Alosetron in blood was evaluated at room temperature.  Two sets (each six 
replicates) of low and high quality control samples were spiked in blood samples and one 
set of samples immediately centrifuged and plasma was harvested (Comparison samples). 
Another set of QC samples kept at room temperature for approximately 02 hours 06 
minutes and plasma was harvested after centrifugation, all the samples were processed as 
per method SOP and analyzed in a single batch. The % stability in blood was calculated 
using response, found to be stable in human blood for 02 hours 06 minutes at room 
temperature with % stability of 100.00 and 99.71 for LQC and HQC respectively. Results 
are presented in Table 30.
Table 30: Stability of Analyte in Blood
Stability Duration : 2 hour 06 minutes
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QC ID
Comparison Sample Area Ratio Stability Sample Area Ratio
LQC HQC LQC HQC
ANALYTE 
RESPONSE
0.041 2.071 0.045 2.053
0.047 2.075 0.041 2.081
0.041 2.114 0.044 2.145
0.044 2.099 0.042 2.072
0.040 2.065 0.041 2.039
0.043 2.141 0.043 2.138
AVERAGE 0.043 2.094 0.043 2.088
SD 0.003 0.030 0.002 0.044
%CV 6.98 1.43 4.65 2.11
% STABILITY 100.00 99.71
6.16 SOP DEVIATIONS
There were no significant deviations observed.
6.17 CONCLUSION
A selective and sensitive Liquid Chromatography-Mass Spectrometry/Mass Spectrometry 
method to quantitate Alosetron in K2EDTA human plasma over the concentration range 
0.160 to 28.920 ng/mL was successfully validated. This method is suitable for sample 
analysis to support bioequivalence/bioavailability and/or pharmacokinetic studies of 
Alosetron. 
Chronology of validation runs are shown in Table 31.
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Table 31: Chronology of Validation Runs
Acquisition 
Date
Validation Parameters Batch ID
Instrument 
ID
Status
Reason for 
Failure
13/08/13 Selectivity SPE&SEL BA-MS-07 Accepted NA
13/08/13 Matrix Effect ME BA-MS-07 Accepted NA
14/08/13
Precision and Accuracy Batch 
1
PA 01 BA-MS-07 Accepted NA
14/08/13 Carry Over Test ASCOT BA-MS-07 Accepted NA
14/08/13
Precision and Accuracy Batch 
2 & Recovery
PA02 & REC BA-MS-07 Accepted NA
14/08/13 Carry Over Test ASCOT BA-MS-07 Accepted NA
14/08/13 Ruggedness RUG BA-MS-08 Accepted NA
14/08/13 Carry Over Test ASCOT BA-MS-08 Accepted NA
14/08/13
Short Term Stock Solution 
Stability
STSS BA-MS-08 Accepted NA
15/08/13 Reinjection Reproducibility RIR BA-MS-08 Accepted NA
15/08/13
Working Solution Stability in 
Room Temperature
WSS_RT BA-MS-08 Accepted NA
15/08/13
Precision and Accuracy Batch 
3 & Dilution Integrity
PA 03 BA-MS-08 Not Accepted
% CV for LLOQ 
samples not 
within the limit
15/08/13
Production Batch Precision & 
Accuracy
PBPA BA-MS-07 Not Accepted
% CV for LQC 
samples not 
within the limit
16/08/13
Precision and Accuracy Batch 
4 & Dilution Integrity
PA 04 BA-MS-08 Accepted NA
16/08/13
Freeze Thaw Stability at -70ºC 
and -20 ºC (FTS)
STABILITY 1 BA-MS-08 Accepted NA
Bench Top Stability (BTS) STABILITY 1 BA-MS-08 Accepted NA
16/08/13 Wet Extract Stability at Room STABILITY 2 BA-MS-07 Accepted NA
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Temperature (WES_RT)
Wet Extract Stability at 
Refrigerator (WES_RF)
STABILITY 2 BA-MS-07 Accepted NA
Auto Sampler Stability (ASS) STABILITY 2 BA-MS-07 Not Accepted
% CV & Stability 
for  LQC samples 
not within the 
limit
16/08/13
Production Batch Precision & 
Accuracy
PBPA BA-MS-07 Accepted NA
17/08/13
Working Solution Stability in 
Refrigerator
WSS_RF BA-MS-08 Accepted NA
17/08/13 Auto Sampler Stability (ASS) STABILITY 3 BA-MS-08 Accepted NA
17/08/13 Analyte Stability in Blood ASB BA-MS-08 Accepted NA
30/08/13
Long term stock solution 
stability- 18 days
LTSS BA-MS-08 Accepted NA
30/08/13
Long Term Stability of 
Analyte in Matrix- 17 days
LTMS BA-MS-08 Accepted NA
ACCEPTANCE CRITERIA
Experiment Acceptance Criteria
Carry Over Test
o Peak response obtained in the blank sample at the retention time of 
analyte and IS should be less than 20 % and 5% of mean LLOQ 
response.
Selectivity
o Response of the interfering peaks at the retention time of 
analyte(s) should be ≤20% of the response of analyte(s) in LLOQ 
standard.
o Response of the interfering peaks at the retention time of IS should 
be ≤5% of IS responses in LLOQ Standard.
o At least 80% of the screened matrix lots should meet the 
acceptance criteria including lipimic and haemolysed lot.
Matrix effect
o CV % of the analyte matrix factor and IS normalized matrix factor 
calculated from different lots of matrix should not be greater than 
15% at each level.
Sensitivity
o Limit of Quantification is acceptable if mean of 6 determinations 
is within ± 20% of the nominal concentration and precision (CV) 
is ≤ 20%.
o Signal to noise shall be more than 5. 
Linearity o Percentage interference at the retention time of analyte(s) in any of 
duplicates of blank matrix and zero standards should not be more 
than 20% of the accepted LLOQ response.
99
o Percentage interference at the retention time of the internal 
standard in any of duplicates of blank matrix should not be more 
than 5% of the mean of the accepted CC standards IS response.
o Accuracy (% Nominal) of calibration standards should be within ± 
15% from the nominal concentration other than LLOQ where it 
should be within ± 20%.
o At least 75% or a minimum of 6 non-zero standards should meet 
the given acceptance criteria including LLOQ and ULOQ.
o Correlation coefficient (r) should be ≥0.99 or coefficient of 
determination (r2) should be ≥0.98.
Precision & Accuracy
o Back calculated values of at least 67% (20 out of 30) of total QC 
samples (4 out of 6) at each level (LQC,IMQC, MQC, & HQC) 
should be within ±15% of the nominal concentration except LLOQ 
where it should be within ± 20%.
o Accuracy: within and between batch mean concentration (% 
Nominal) should be within ± 15% at each level except LLOQ 
where it should be within ± 20%.
o Precision: within and between day batch precision (% CV) for all 
QC concentrations should be ≤ 15% except LLOQ where it should 
be ≤ 20%.
Recovery 
o Recovery of analyte(s) is acceptable if % CV is ≤ 15% for low, 
middle and high QC concentration, individually and totally. 
o Recovery of internal standard is acceptable if % CV is ≤ 15%
o Recovery should not be more than 115%.
Dilution Integrity
o The DI is acceptable if the mean % nominal is within ± 15% and 
CV is ≤ 15%.
o 67% of total DI samples should be within ± 15% of nominal value.
Ruggedness o As given for Precision & Accuracy 
Re-injection 
Reproducibility
o Back calculated values of at least 67% of total QC samples (4 out 
of 6) at each level should be within ±15% of the nominal 
concentration. 
o Precision: CV for QC concentrations should be ≤ 15%.
Production Batch P&A
o Back calculated values of at least 67% of total QC samples at each 
level should be within ±15% of the nominal concentration. 
o Precision: CV for QC concentrations should be ≤ 15%.
Stability
Stock solution stability
o Percentage stability of analyte(s) and IS stocks should be within 
the range of 90 - 110% for both short term and long term stock 
solution stability
Working Solution 
Stability
o Percentage stability of analyte(s) and IS working solutions should 
be within the range of 90 - 110%.
Auto Sampler stability
o Auto sampler stability should be within 85-115% and precision 
(CV) should be ≤15% at HQC and LQC levels.
o At least 67% of QCs per level must be within 85-115%.
Wet Extract stability
o The wet extract Stability of the Analyte(s) should be within 85-
115% and precision (CV) should be ≤ 15% at HQC and LQC 
levels.
o At least 67% of QCs per level must be within 85-115%.
Dry Extract Stability
o The dry Extract Stability of the Analyte(s) should be within 85-
115% and precision (CV) should be ≤ 15% at HQC and LQC 
levels.
o At least 67% of QCs per level must be within 85-115%.
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Bench Top Stability
o Bench top stability of the analyte(s) should be within 85-115% 
and precision (CV) should be ≤ 15% at LQC and HQC levels.
o At least 67% of QCs per level must be within 85-115%.
Freeze Thaw Stability
o Freeze-Thaw Stability of the Analyte(s) should be within 85-115% 
and precision (CV) should be ≤ 15% at HQC and LQC levels.
o 67% of total Comparison samples must be 85-115%.
Stability of Analyte in 
Blood
o The stability of the analyte(s) should be within the range of 85-
115% 
o 67% of total Comparison samples must be 100 ± 15% nominal 
value.
o CV of should be ≤ 15% at HQC and LQC levels.
Long Term stability in 
Matrix
o Long term stability in matrix of the analyte(s) should be within the 
range of 85-115%. 
o 67% of total Comparison samples must be 100 ± 15% nominal 
value.
o CV of should be ≤ 15% at HQC and LQC levels.
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CHROMATOGRAMS
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CHROMATOGRAMS
Figure 1.  Representative chromatogram of processed blank matrix.
Figure 2.   Representative chromatogram of lower limit of quantification sample    containing 
Alosetron (0.160 ng/mL) in matrix
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Figure 3.   Representative chromatogram of low quality control sample containing Alosetron 
(0.460 ng/mL) in matrix.
Figure 4.    Representative chromatogram of medium quality control sample containing 
Alosetron (9.100 ng/mL) in matrix.
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Figure 5.  Representative chromatogram of high quality control sample containing Alosetron 
( 22.760 ng/mL) in matrix.
Figure 6.  Representative chromatogram of upper limit of quantification sample containing 
Alosetron (28.920 ng/mL) in matrix.
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Figure 7. Representative calibration curve for Alosetron in matrix
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SUMMARY AND CONCLUSION
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SUMMARY
          A LC-MS/MS method for the determination of Alosetron in human K2EDTA plasma is 
described in method SOP No. BM-020-02. The method was validated according to SOP NO.: EBL-
BA-24-02. 
Parameters Results
Calibration curve Range 0.160 to 28.920 ng/mL
Coefficient of determination (r2 ) Greater than 0.9991
Between-Run Accuracy QC % nominal concentrations: 98.58 to 108.13 % 
Between-Run Precision QC coefficient of variation: 0.66 to 10.98 %
Within- Run Accuracy QC % nominal concentrations: 98.13 to 118.13 %
Within- Run Precision QC coefficient of variation: 0.35  to 12.70 %
Selectivity 92.3 % & 100 % of tested matrix was within the limit for 
Analyte and IS
Sensitivity (LLOQ) 0.160  ng/mL
Sensitivity -Accuracy QC % nominal concentrations:  99.38 %
Sensitivity-Precision QC coefficient of variation: 1.26 %
Dilution Integrity- Accuracy (1/2 and 1/4) QC % nominal concentrations: 99.53 and 98.81 %
Dilution Integrity-Precision (1/2 and 1/4) QC coefficients of variation; 1.12 and 0.48 %
Matrix Effect (LQC & HQC)
Analyte – 2.43 and 1.59 %.  IS normalized – 4.49 and 
3.18 %
Ruggedness- Accuracy QC % nominal concentrations: 99.70 to 107.50 %
Ruggedness- Precision QC coefficients of variation; 0.53 to 2.91 %
Recovery - Analyte LQC-77.36 %, MQC-74.39 %, HQC-75.37 % and Global-
Recovery - IS 79.34 %
Auto sampler Stability (LQC & HQC) Stability after 21 h 40 min  : 99.79 & 100.14 %
Wet Extract Stability in Room temperature (LQC & Stability after 25 h 45 min  : 91.06 & 96.48 %
Wet Extract Stability in Refrigerator (LQC & HQC) Stability after 46 h 44 min  : 95.93 & 95.88 %
Freeze Thaw Stability (-20 ± 5°C)  (LQC & HQC) Stability after 4 cycles: 99.79 & 100.50 %
Freeze Thaw Stability (-70 ± 20 °C)   (LQC & HQC) Stability after 4 cycles: 99.79 & 100.54 %
Short-Term Stock Solution Stability - Analyte Stability after 20 h 57 min  : 99.57 %
Short-Term Stock Solution Stability - IS Stability after 20 h 57 min  : 99.35 %
Working solution stability in Room temperature - Stability after 17 h 20 min  : LQC  95.85 & HQC  100.26 
Working solution stability in Room temperature - IS Stability after 17  h 20 min  : 100.23 %
Working solution stability in Refrigerator - Analyte Stability after 64 h 56 min: LQC  98.74 & HQC  99.28 %
Working solution stability in Refrigerator - IS Stability after 64 h 56 min: 99.26 %
Bench top stability(LQC & HQC) Stability after 16 h 25 min  : LQC 101.95 & HQC 101.05 
Long term stock solution stability- Analyte Stability after 18 days  : 100.67%
Long term stock solution stability- IS Stability after 18 days  : 97.99 %
Long Term stability of analyte in K2EDTA Plasma (- Stability after 17 days: LQC  112.10 & HQC 96.38 %
Long Term stability of analyte in K2EDTA Plasma (- Stability after 17 days: LQC  108.90 & HQC 96.59 %
Stability of Analyte in Blood Stability after 2 h 06 min LQC 100.00 & HQC 99.71 %
          Alosetron is extracted from an aliquot of human K2EDTA plasma using Protein precipitation 
method and injected into a liquid chromatography equipped with tandem mass spectrometry 
detector. Quantitation was done by peak area ratio method. A weighted (1/X2) linear regression is 
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performed to determine the concentration of the analyte. Results obtained from this validation are 
presented in Tables 1-31. This method demonstrates acceptable performance as outlined by EBL 
SOPs and is suitable for the determination of Alosetron in human K2EDTA plasma over the range 
0.160 to 28.920 ng/mL. 
CONCLUSION
The proposed method demonstrates good stability conditions for drug in biological matrix.
This method is beneficial in the following aspects
 Less expensive
 Less matrix interference
The proposed sample preparation technique gives precise, accurate and reproducible response with 
a considerably short term analysis.
A selective and sensitive Liquid Chromatography-Mass Spectrometry/Mass Spectrometry method 
to quantitate Alosetron in K2EDTA human plasma over the concentration range from 0.160 to 
28.920 ng/ml was successfully validated. This method is suitable for sample analysis to support 
bioequivalence/bioavailability and/or pharmacokinetic studies of Alosetron. 
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